WO2011005738A1 - Bace inhibitors - Google Patents

Bace inhibitors Download PDF

Info

Publication number
WO2011005738A1
WO2011005738A1 PCT/US2010/041034 US2010041034W WO2011005738A1 WO 2011005738 A1 WO2011005738 A1 WO 2011005738A1 US 2010041034 W US2010041034 W US 2010041034W WO 2011005738 A1 WO2011005738 A1 WO 2011005738A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
compound
mixture
thiazin
pharmaceutically acceptable
Prior art date
Application number
PCT/US2010/041034
Other languages
French (fr)
Inventor
James Edmund Audia
Dustin James Mergott
Chongsheng Eric Shi
Grant Mathews Vaught
Brian Morgan Watson
Leonard Larry Winneroski, Jr.
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011005738(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP10731890.9A priority Critical patent/EP2451793B1/en
Priority to CN201080030698.1A priority patent/CN102471296B/en
Priority to NZ596579A priority patent/NZ596579A/en
Priority to MX2012000510A priority patent/MX2012000510A/en
Priority to BR112012000525A priority patent/BR112012000525A2/en
Priority to KR1020127000457A priority patent/KR101362557B1/en
Priority to MA34517A priority patent/MA33492B1/en
Priority to AU2010270691A priority patent/AU2010270691B8/en
Priority to JP2012519660A priority patent/JP5666578B2/en
Priority to CA2764429A priority patent/CA2764429C/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to SG2012001749A priority patent/SG177594A1/en
Priority to EA201270149A priority patent/EA019892B1/en
Publication of WO2011005738A1 publication Critical patent/WO2011005738A1/en
Priority to IL216742A priority patent/IL216742A0/en
Priority to ZA2011/09385A priority patent/ZA201109385B/en
Priority to TNP2011000673A priority patent/TN2011000673A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention is in the field of treatment of Alzheimer's disease and other diseases and disorders involving amyloid ⁇ (A ⁇ ) peptide, a neurotoxic and highly aggregatory peptide segment of amyloid precursor protein (APP).
  • a ⁇ amyloid ⁇
  • APP amyloid precursor protein
  • BACE ⁇ -secretase or ⁇ -site amyloid precursor protein-cleaving enzyme
  • BACE inhibitors are peptidomimetic transition state analogs, typically containing a hydroxy ethyl moiety. Although many of these compounds are potent inhibitors of BACE, their high molecular weights and low membrane permeability make them poor drug candidates. See Park and Lee, Journal of the American Chemical Society, 125(52), 16416-16422 (2003). There has been a progression from large peptidomimetic molecules to small molecules, such as a variety of hydroxy ethylamine scaffolds as well as heterocyclic-containing scaffolds. See e.g., Durham and Shepherd, Current Opinion in Drug Discovery & Development, 9(6), 776-791 (2006). Certain aminothiazine compounds have been described as BACE inhibitors in WO 2007/049532, WO 2008/133273, and WO 2008/133274.
  • BACE inhibitors that are potent and more efficacious are necessary to provide treatments for A ⁇ peptide-mediated disorders, such as Alzheimer's disease.
  • the present invention provides new potent and efficacious inhibitors of BACE.
  • the present invention provides compounds of Formula I:
  • X is -CH 2 - or -O-;
  • n 0 or 1 ;
  • n 0, 1, or 2;
  • p is 0 or 1 ; p must be 0 when X is -O-;
  • R 1 is -NHCOR 4 , pyrimidinyl, pyridinyl optionally substituted with halo or phenyl optionally monosubstituted with -C 1 -C 3 alkoxy;
  • R 2 is halo
  • R 3 is -Ci -C 3 alkoxy, hydroxy, or -0-CH 2 -O-CH 3 ;
  • R 4 is phenyl, pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl;
  • the present invention also provides a method of treating Alzheimer's disease in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention.
  • the present invention further provides a method of preventing the progression of mild cognitive impairment to Alzheimer's disease in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the present invention further provides a method of preventing the progression in a patient at risk for developing Alzheimer's disease comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method of inhibiting BACE in a patient comprising administering to a mammal in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a method for inhibiting BACE-mediated cleavage of amyloid precursor protein comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the present invention further provides a method for the inhibition of production of A ⁇ peptide comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • the present invention also provides a pharmaceutical formulation comprising a compound of the invention or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
  • the formulation further comprises one or more other therapeutic agents.
  • this invention provides a compound of the invention or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment of Alzheimer's disease or for the prevention of the progression of mild cognitive impairment to Alzheimer's disease. Even furthermore, this invention provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Alzheimer's disease. This invention also provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention of the progression of mild cognitive impairment to Alzheimer's disease. The invention also provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of BACE. The invention further provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of production of A ⁇ peptide.
  • this invention provides a pharmaceutical formulation adapted for the treatment of Alzheimer's disease. Furthermore, this invention provides a pharmaceutical formulation adapted for the prevention of the progression of mild cognitive impairment to Alzheimer's disease. This invention also provides a pharmaceutical formulation adapted for the inhibition of BACE.
  • the present invention provides a pharmaceutical formulation adapted for the inhibition of BACE-mediated cleavage of amyloid precursor protein.
  • the present invention also provides a pharmaceutical formulation adapted for the treatment of conditions resulting from excessive levels of A ⁇ peptide comprising a compound of the -A-
  • -C 1 -C 3 alkoxy is a -C 1 -C 3 alkyl group bonded to an oxygen atom and refers to methoxy, ethoxy, propoxy, and ⁇ o-propoxy.
  • halo refers to fluoro and chloro.
  • nitrogen protecting group is taken to mean a moiety that is stable to projected reaction conditions and yet may be selectively removed by reagents and reaction conditions compatible with the regenerated amine.
  • Such groups are well known by the skilled artisan and are described in the literature. See, e.g., Greene and Wuts,
  • inhibitors of production of A ⁇ peptide are taken to mean decreasing of in vivo levels of A ⁇ peptide in a mammal.
  • effective amount of a compound of Formula I is taken to mean the dose or doses of a compound of the invention required to inhibit BACE sufficiently to decrease in vivo levels of A ⁇ peptide in a mammal.
  • Mild cognitive impairment has been defined as a potential prodromal phase of dementia associated with Alzheimer's disease based on clinical presentation and on progression of patients exhibiting mild cognitive impairment to Alzheimer's dementia over time.
  • Mild cognitive impairment has been defined as a potential prodromal phase of dementia associated with Alzheimer's disease based on clinical presentation and on progression of patients exhibiting mild cognitive impairment to Alzheimer's dementia over time.
  • prevention of the progression of mild cognitive impairment to Alzheimer's disease includes slowing, arresting, or reversing the progression of mild cognitive impairment to Alzheimer's disease in a patient.
  • the skilled artisan will also appreciate that the Cahn-Ingold-Prelog (R) or (S) designations for all chiral centers will vary depending upon the substitution patterns of the particular compound.
  • the single enantiomers or diastereomers may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques. Alternatively, the single enantiomers or diastereomers may be isolated from mixtures by standard chiral chromatographic or crystallization techniques at any convenient point in the synthesis of compounds of the invention. Single enantiomers and diastereomers of compounds of the invention are a preferred embodiment of the invention.
  • the compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts.
  • Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al. Handbook of Pharmaceutical Salts: Properties, Selection and Use, (VCHA/Wiley-VCH, 2002); S.M. Berge, et al, "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977.
  • Preferred pharmaceutically acceptable salts are those formed with hydrochloric acid.
  • n 0;
  • n 1;
  • h) p must be 0 when X is -O-;
  • R 1 is pyridinyl
  • R 1 is pyridinyl optionally substituted with -Cl and -F;
  • R 1 is pyrimidinyl
  • R 1 is pyrimidinyl or pyridinyl optionally substituted with halo
  • R 1 is -NHCOR 4 , pyrimidinyl, or pyridinyl optionally substituted with -Cl and
  • R 1 is -NHCOR 4 , phenyl optionally substituted with -C 1 -C 3 alkoxy, pyrimidinyl, or pyridinyl optionally substituted with -Cl and -F; r) R 1 is -NHCOR 4 , phenyl optionally substituted with -C 1 -C 3 alkoxy, or
  • R 1 is -NHCOR 4 or pyrimidinyl
  • R 2 is fluoro
  • R 3 is -C 1 -C 3 alkoxy or hydroxy
  • R 3 is -OCH 3 , -OCH 2 (CHs) 2 , or hydroxy;
  • R 4 is phenyl
  • R 4 is thiazolyl
  • R 4 is pyridinyl optionally substituted with -Cl or -F, pyrimidinyl optionally substituted with halo, or pyrizinyl;
  • R 4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally
  • R 4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally
  • R 4 is pyridinyl optionally substituted with halo or pyrimidinyl optionally substituted with halo;
  • R 4 is pyridinyl
  • R 4 is pyridinyl optionally substituted with halo
  • R 4 is pyridinyl optionally substituted with fluoro
  • the compound of the invention has a cis configuration at the chiral centers at the junction of the fused aminothiazine ring;
  • the compound of the invention is a free base
  • the compound of the invention is a pharmaceutically acceptable salt
  • the compound of the invention is the hydrochloride salt
  • the compound of the invention is the dihydrochloride salt.
  • the compound of the invention is the ethanesulfonate salt.
  • the compound of the invention is thep-toluenesulfonate salt.
  • a preferred embodiment of the compounds of the present invention relates to compounds of the invention, wherein X is -CH 2 - or -0-; n is O or 1; m is O, 1, or 2; p is 0 or 1 ; p must be 0 when X is -O-;R X is -NHCOR 4 , pyrimidinyl, or pyridinyl optionally substituted with halo; R 2 is fluoro; R 3 is -C 1 -C 3 alkoxy or hydroxy; R 4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl; or a pharmaceutically acceptable salt thereof.
  • halo is chloro or fluoro when R 4 is pyridinyl or chloro when R 4 is pyrimidinyl.
  • the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
  • Another preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH 2 - or -O-; n is 0 or 1 ; m is 0 or 1 ; p is 1 ; p must be 0 when X is -O-;R X is -NHCOR 4 , phenyl optionally substituted with -C 1 -C 3 alkoxy, pyrimidinyl, or pyridinyl optionally substituted with halo; R is fluoro; R is -C 1 - C 3 alkoxy or hydroxy; R 4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, or thiazolyl; or a pharmaceutically acceptable salt thereof.
  • halo is chloro or fluoro when R 4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof.
  • R 4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof.
  • the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
  • a more preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH 2 - or -O-; n is 0 or 1; m is 0, 1, or 2; p is 0 or 1; p must be 0 when X is -O-;R X is -NHCOR4 or pyrimidinyl; R 2 is fluoro; R 3 is -C 1 - C3 alkoxy or hydroxy; R 4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl; or a pharmaceutically acceptable salt thereof.
  • halo is chloro or fluoro when R 4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof.
  • R 4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof.
  • the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
  • a further embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH 2 - or -O-; n is 0 or 1; m is 0 or 1; p is 0 or 1; p must be 0 when X is -O-;R X is -NHCOR 4 , phenyl optionally substituted with -C 1 -C 3 alkoxy, or pyrimidinyl; R 2 is fluoro; R 3 is -C 1 -C 3 alkoxy or hydroxy; R 4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl; or a pharmaceutically acceptable salt thereof.
  • halo is chloro or fluoro when R 4 is pyridinyl or pyrimidinyl.
  • R 4 is pyridinyl or pyrimidinyl.
  • the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
  • a most preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH 2 - or -O-; n is 0 or 1; m is 0 or 1; p is 0 or 1; p must be 0 when X is -O-;R X is -NHCOR 4 or pyrimidinyl; R 2 is fluoro; R 3 is -C 1 -C 3 alkoxy or hydroxy; R 4 is pyridinyl optionally substituted with halo, or pyrimidinyl optionally substituted with halo; or a pharmaceutically acceptable salt thereof.
  • halo is chloro or fluoro when R 4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof.
  • R 4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof.
  • the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
  • Another most preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH 2 - or -O-; n is 0 or 1; m is 0 or 1; p is 0; R 1 is -NHCOR 4 ; R 2 is fluoro; R 4 is pyridinyl optionally substituted with halo; or a pharmaceutically acceptable salt thereof.
  • halo is chloro or fluoro when R 4 is pyridinyl; or a pharmaceutically acceptable salt thereof.
  • An especially preferred embodiment of the compounds of the present invention relates to compounds of Formula I wherein X is -O-; n is 0; m is 1; p is 0; R 1 is
  • R 2 is halo;
  • R 4 is pyridinyl substituted with halo; or a pharmaceutically acceptable salt thereof.
  • R is fluoro; or a pharmaceutically acceptable salt thereof.
  • the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
  • the compounds of Formula I are inhibitors of BACE.
  • the present invention also provides a method of inhibiting BACE in a mammal that comprises administering to a mammal in need of said treatment a BACE-inhibiting amount of a compound of Formula I. It is preferred that the mammal to be treated by the administration of the compounds of Formula I is human.
  • the compounds of the present invention are useful for suppressing the production of A ⁇ peptide, and therefore for the treatment of disorders resulting from excessive A ⁇ peptide levels due to over-production and/or reduced clearance of A ⁇ peptide.
  • a further embodiment of the present invention is the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by inhibition of BACE.
  • the compounds of Formula I are therefore believed to be useful in treating or preventing Alzheimer's disease, mild cognitive impairment, Down's Syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, other degenerative dementias such as: dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated cortical basal degeneration, and diffuse Lewy body type of Alzheimer's disease.
  • the compounds of the present invention, or salts thereof may be prepared by a variety of procedures known in the art, some of which are illustrated in the Schemes, Preparations, and Examples below.
  • ⁇ BTU O-benzotriazole-N,N,N',N'-tetramethyl-uronium- hexafluoro-phosphate
  • ⁇ OAt refers to l-hydroxy-7-azabenzotriazole
  • iPrO ⁇ refers to isopropanol
  • MeOH refers to methyl alcohol or methanol
  • (OEt) refers to ethoxide
  • PyBOP refers to benzotriazol-1-yloxytripyrrolidino-phosphonium
  • T ⁇ F trifluoroacetic acid
  • EtOH ethyl alcohol or ethanol
  • SCX strong cation exchange
  • T R retention time
  • IC50 concentration of an agent that produces 50% of the maximal inhibitory response possible for that agent
  • APP amyloid precursor protein
  • DMEM Dulbecco's Modified Eagle's Medium
  • F12 refers to Ham's F12 medium
  • FBS Fetal Bovine Serum
  • FRET fluorescence resonance energy transfer
  • HEK refers to human embryonic kidney
  • PDAPP platelet derived amyloid precursor protein
  • RU refers to relative fluorescence unit.
  • Scheme I depicts the acylation of an appropriate amine compound of formula (1) with an aryl carboxylic acid of formula (2) to give a compound of formula (I) after the deprotection of the intermediate (3).
  • PG is a protecting group developed for the amino group, such as carbamates and amides. Such protecting groups are well known and appreciated in the art.
  • a compound of formula (1) is reacted with a compound of formula (2) under coupling conditions.
  • a compound of formula (2) under coupling conditions.
  • a coupling reagent and an amine base such as DIPEA or triethylamine
  • Coupling reagents include carbodiimides, such as DCC, DIC, EDCI, and aromatic coupling reagents, such as HOBt and HOAt.
  • uronium or phosphonium salts of non- nucleophilic anions such as HBTU, HATU, PyBOP, and PyBrOP can be used in place of the more traditional coupling reagents.
  • Additives such as DMAP may be used to enhance the reactions.
  • a compound of formula (1) can be acylated using substituted benzoyl chlorides in the presence of a base, such as triethylamine or pyridine.
  • the protecting group in intermediate (3) can be removed under acidic or basic conditions to give the compounds of formula (1).
  • the deprotection of such compounds is well known and appreciated in the art.
  • a pharmaceutically acceptable salt of a compound of Formula (I) can be formed by reaction of an appropriate free base of Formula (I) with an appropriate pharmaceutically acceptable acid in a suitable solvent under standard conditions. Additionally, the formation of such salts can occur simultaneously upon deprotection of a nitrogen protecting group. The formation of such salts is well known and appreciated in the art.
  • Scheme II depicts the alkylation of an appropriate compound of formula (4) with an aryl boronic acid (5) to give a compound of formula I after deprotection of the intermediate (6).
  • Y is trifluoromethanesulfonyl or a halogen, such as Br or I.
  • R 1 is an aryl group, such as phenyl, or a heteroaryl group, such as pyridinyl.
  • a suitable palladium reagent includes bis(triphenylphosphine)palladium(II) chloride, tris(dibenzylideneacetone)dipalladium (O) with tricyclohexylphosphine, (1,1 '-bis(diphenylphosphino)ferrocene)palladium(II) chloride, palladium tetrakistriphenylphosphine, or palladium(II) acetate.
  • a suitable base includes cesium carbonate, sodium carbonate, potassium carbonate, or potassium phosphate tribasic monohydrate.
  • the protecting group can be removed under acidic or basic conditions to give bi- aryl compounds of formula I.
  • the deprotection of such compounds is well known and appreciated in the art.
  • Scheme III depicts two variations to prepare the primary amine (1) starting from an appropriate aryl bromide (7).
  • azido-dehalogenation is performed on the appropriate aryl bromide (7) in the presence of an azide source, such as sodium azide.
  • an azide source such as sodium azide.
  • Reduction of the resulting azide (8) to the primary amine (1) may be effected by using a number of reducing agents well known in the art, such as LiAlH 4 , NaBH 4 , PPI13, or via
  • the appropriate primary amine (1) can be prepared directly by reacting an appropriate aryl bromide (7) with an ammonia surrogate, such as trifluoroacetamide in the presence of a catalyst, such as copper iodide, a base, such as potassium carbonate, and a ligand, such as (+/-) trans N,N'-dimethyl 1,2- cyclohexanediamine.
  • an ammonia surrogate such as trifluoroacetamide
  • a catalyst such as copper iodide
  • a base such as potassium carbonate
  • a ligand such as (+/-) trans N,N'-dimethyl 1,2- cyclohexanediamine
  • compounds of formula (7) can be promptly prepared by methods similar to those described herein by procedures that are well-known and established in the art. As will be readily understood, the steps to prepare the compounds of formula I are dependent upon the particular compound being synthesized, the starting compound, and the relative lability of the substituted moieties.
  • the mass spectrometry data is obtained via LC/MS: Phenomenex Gemini C 18 (2.0 x 50 ⁇ m, 3.5 ⁇ m) column at a temperature of 50 0 C +/- 10 0 C with a flow rate of 1 mL/min.
  • the elution system is 5 to 100% AC ⁇ w/ 0.1% ammonium hydroxide for 7.0 minutes then held at 100% AC ⁇ for 1.0 minute coupled with electrospray ionization (100-800 amu scan range; 0.2 amu step; 80v Fragmentor; 1.0 gain; 80 threshold).
  • the gas chromatography data unless specified otherwise is obtained via GC/MS: Agilent gas chromatography DB-5ms (0.25 mm x 15 m x 0.25 ⁇ m) with a temperature program of 60 - 280 0 C in 7.3 minutes then held at 280 0 C for 2.0 minutes and a split ratio of 20:1.
  • Tetrabutylammonium hydrogenosulfate (470 g, 1.40 mol) is added to a solution of sodium hydroxide (6.6 Kg, 165 mol) in water (14 L) and toluene (14 L) at 20 0 C.
  • AHyI alcohol 801.5 g, 13.8 mol is added and the mixture is stirred at 20 0 C for Ih.
  • the mixture is cooled to 5 0 C, and tert-butyl 2-bromoacetate (4 Kg, 20.5 mol) is added slowly maintaining the internal temperature below 15 0 C.
  • the reaction mixture is stirred at room temperature for 16 h.
  • the mixture is diluted with water (12 L) and hexanes (12 L) and the organic phase is separated.
  • Zinc powder (190 g, 2.91 mol) is added to a mixture of racemic (3aSR,6aSR)-6a- (5-bromo-2-fluorophenyl)hexahydrofuro[3,4-c]isoxazole (84 g, 290 mmol) in acetic acid (1.4 L) at a rate maintaining the temperature below 30 0 C.
  • the reaction is heated at 40 0 C for 5 h.
  • the reaction is cooled to room temperature and is filtered through a pad of diatomaceous earth, washed with acetic acid and water (200 mL). The solvent is removed under reduced pressure. Water (500 mL) is added to the residue, and the pH is adjusted to pH 10 with 2 M aqueous sodium hydroxide.
  • Racemic N-((4aSR,7aSR)- (7a(5-bromo-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-(/][l,3]thiazin-2-yl)benzamide (108 g, 248 mmol) is purified by chiral ⁇ PLC: Chiralcel OJ- ⁇ 8 x 25 cm column; eluent: 90 : 10 (methanol : acetonitrile) with 0.2% dimethylethylamine; flow: 300 mL/min at UV 254 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (42.0 g, 40%). ES/MS m/e ( 7 W 1 Br) 434.9/436.9 (M+ 1).
  • Aqueous hydrochloric acid (158 mL) is added to N-(7a-(5-bromo-2- fluorophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2-yl)benzamide (16.35 g, 7.89 mmol) and the mixture is heated to 90 0 C. After 18 hours, the mixture is allowed to cool to ambient temperature and washed with dichloromethane. The organic layer is extracted once with 5 ⁇ aqueous hydrochloric acid.
  • 1,4-dioxane (731 mL) (previously degassed with vacuum-nitrogen) is added via cannula, and N,N'-dimethyl-, trans (+/-) 1 ,2-cyclohexanediamine (10.1 g, 70.8 mmol) is added.
  • the mixture is placed in a preheated oil bath at 100 0 C and stirred at this temperature for 19 h.
  • the septum is replaced by a reflux condenser and a mixture of methanol (154 mL) and water (154 mL) is added through the condenser.
  • the mixture is stirred at 100 0 C for 3.5 h, cooled to 22 0 C, and concentrated partially under reduced pressure (to 0.6 L volume).
  • Aqueous ammonium hydroxide (25%, 154 mL) is added and the mixture is stirred for 10 min.
  • the mixture is extracted three times with ethyl acetate (3 X 500 mL) and the solvent is removed under reduced pressure.
  • a residue is obtained that is purified by flash chromatography with a linear gradient of 50% to 75% ethyl acetate in hexane to give the title compound (14.9 g, 47%).
  • a 0.66 M solution of L-ascorbic acid is prepared by dissolving L-ascorbic acid sodium salt (0.79 g, 2.0 mmol) in water (6 mL). N-((4aS,7aS)-7a-(3-bromophenyl)- 4a,5,7,7a-tetrahydro-4H-fiiro[3,4-d][l,3]thiazin-2-yl)benzamide (1.40 g, 3.35 mmol) and 1,2-cyclohexanediamine, N,N'-dimethyl-, trans (+/-) (162 mg, 1.11 mmol) are dissolved in ethanol (13.4 mL).
  • N-((4aS,7aS)-7a-(3-azidophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin- 2-yl)benzamide (0.62 g, 1.63 mmol) is diluted with ethanol (10 mL) and Pd on carbon (10%, wet, 0.062 g). The mixture is degassed and stirred at room temperature under hydrogen (30 psi) overnight. The mixture is filtered through diatomaceous earth using ethanol as a rinse. The solvent is removed under reduced pressure to give the title compound, (0.106 g, 18%). ES/MS m/e: 354 (M+l).
  • Iron powder (16.49 g, 291 mmol) is added to 1 -bromo-2,4-difluorobenzene (110 mL, 968 mmol) in 1,2-dichloroethane (968 mL) in a 3 -neck flask at ambient temperature under a stream of nitrogen.
  • 1,2-dichloroethane (968 mL) is added dropwise over 1 hour and the reaction mixture is stirred at ambient temperature for 18 h.
  • the reaction mixture is cooled to 0 0 C and a saturated aqueous solution of sodium bisulfite (1.11 L, 533 mmol) is added portionwise and the mixture is separated.
  • the aqueous phase is extracted with dichloromethane.
  • the organic layer is washed with a saturated aqueous solution of sodium bicarbonate, water, and brine.
  • the organic layer is dried over sodium sulfate, and the solvent is removed under reduced pressure to give a residue purified with a pad of silica using diethyl ether to give the title compound (229 g, 76%).
  • Racemic tert-butyl (4aSR,8aSR)-8a-(3-bromophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (2.80 g, 6.55 mmol) is purified by chiral HP LC: Column: Chiralcel OJ 8 x 35 cm; eluent: 75 : 25 (methanol : acetonitrile); flow: 400 mL/min at UV 260 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (1.31 g, 47%). ES/MS m/e ( 79 Br/ 81 Br) 427, 429 (M+l).
  • a 0.33 M solution of copper sulfate is prepared by dissolving copper (II) sulfate pentahydrate (1.0 g, 2.0 mmol) in water (12 mL).
  • a 0.66 M solution of L-ascorbic acid is prepared by dissolving L-ascorbic acid sodium salt (1.58 g, 4.0 mmol) in water (12 mL).
  • Racemic tert-butyl (4aSR,7aSR)-7a-(2-fluoro-5-(5-fluoropicolinamido)phenyl)- 4a,5,7,7a-tetrahydro-4H-fiiro[3,4-d][l,3]thiazin-2-ylcarbamate (0.226 g, 0.460 mmol) is purified by chiral ⁇ PLC: 2.1 x 25 cm Chiralcel OD- ⁇ , 5 micron column, 30% methanol/CO 2 , flow rate: 70 mL/min, UV: 230 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (0.092 g, 41%). ES/MS (m/e): 491 (M+l).
  • the reaction mixture is heated at 110 0 C for 7 hours.
  • the reaction is cooled, diluted with ethyl acetate, and filtered.
  • the resulting filtrate is separated and the aqueous layer is extracted three times with ethyl acetate.
  • the combined organic layers are washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product is purified by silica gel chromatography eluting with 10% to 20% ethyl acetate in hexanes gradient over 20 minutes to give the title compound (7.59 g, 92%).
  • the crude product is purified by silica gel chromatography eluting with a linear gradient of 10% to 40% ethyl acetate in hexanes over 26 minutes to give a crude diastereomeric mixture (7.39 g, 100%).
  • the mixture is purified again on silica gel chromatography to separate the diastereomers eluting with 15% ethyl acetate in hexanes to give the title compound as a racemic mixture (1.47 g, 24%).
  • Racemic N-((4aRS,6RS,7aSR)-6-hydroxy-7a-(3'-methoxybiphenyl-3-yl)- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.689 g, 1.50 mmol) is purified by chiral HPLC: 2.1 x 25 cm Chiralpak AD-H, 5 micron, 35% IPA/CO 2 , flow rate: 70 mL/min, UV: 225 nm. The first eluting isomer is isolated to provide the enantiomerically enriched title compound (0.242 g, 35%). ES/MS m/e: 459 (M+l).
  • the resulting mixture is stirred at 0 0 C for 1 hour, and then is warmed to room temperature over 24 h.
  • the mixture is diluted with dichloromethane, quenched by addition of saturated aqueous solution of sodium bicarbonate, and is extracted three times with dichloromethane.
  • the combined organic layers are washed with water and brine.
  • the organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product is purified by silica gel chromatography eluting with a linear gradient of 0% to 60% ethyl acetate in hexanes over 26 minutes to give the title compound (0.089, 93%).
  • Racemic N-((4aRS,6RS,7aSR)-7a-(3-bromo-4-fluorophenyl)-6-hydroxy- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.492 g, 1.09 mmol) is purified by chiral HPLC: Column: Chiralcel OJ-H 3 x 25 cm; eluent: 75 : 25 (methanol : acetonitrile); flow: 40 mL/min at UV 225 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (0.171 g, 35%).
  • Method A The solid (16 g) is suspended in 240 mL of water and an aqueous solution of 2N sodium hydroxide is added (1.5eq, 3 ImL). The mixture is placed in an ultrasound bath for 15 min at 22 0 C and stirred at 22 0 C for 3 h. The white solid is filtered, washed with water (3 x 100 mL), and dried in a vacuum oven at 45 0 C overnight to yield the title compound (14 g). ES/MS m/e 391(M+1).
  • Method B The solid (3 g) is suspended in methanol (40 mL) and heated between 62 to 64 0 C for 15 h with seeding with seeds of the free base of N-(3-((4aS,7aS)-2-Amino- 4a,5,7,7a-tetrahydro-4H-fiiro[3,4-d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5- fluoropicolinamide. The mixture is cooled to room temperature and the slurry is filtered. The solid is washed with methanol and dried in a vacuum oven at 50 0 C for 4 h to yield the title compound (2.3 g). ES/MS m/e 391 (M+l).
  • the mixture is diluted with dichloromethane and aqueous 0.1 M ⁇ aO ⁇ and is extracted five times with dichloromethane.
  • the combined organic phase is diluted with MeOH to make a homogenous solution, dried over sodium sulfate, filtered, and the solvent is removed under reduced pressure to give a residue that is purified on silica gel with 5% methanol in dichloromethane to give the title compound as the freebase (0.109 g, 51%).
  • Hydrogen chloride is bubbled through the solution of N-(3-((4aS,7aS)-2-amino-4a,5,7,7a- tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-5-fluorophenyl)-5-fluoropicolinamide (0.109 g, 0.279 mmol) in methanol for approximately 5 min.
  • the solution is then concentrated under reduced pressure and dried on high vacuum to yield the title compound (0.128 g, 51%).
  • Aqueous hydrochloric acid (8.70 mL) is added to N-((4aS,7aS)-7a-(2,4- difluoro-5-(5-fluoropyridin-3-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin- 2-yl)benzamide (0.252 g, 0.435 mmol) in methanol (4 mL) and the mixture is heated to 90 0 C. After 18 hours, the heat is removed and the p ⁇ of the reaction mixture is adjusted to basic with 5 ⁇ aqueous sodium hydroxide. The mixture is extracted three times with 10% isopropyl alcohol in dichloromethane.
  • test compounds are prepared in DMSO to make up a 10 mM stock solution.
  • the stock solution is serially diluted in DMSO to obtain a ten-point dilution curve with final compound concentrations ranging from 10 mM to 1 nM in a 96-well round-bottom plate before conducting the in vitro enzymatic and whole cell assays.
  • Serial dilutions of test compounds are prepared as described above. Compounds are further diluted 2OX in KH 2 PO 4 buffer. Ten ⁇ L of each dilution is added to each well on row A to H of a corresponding low protein binding black plate containing the reaction mixture (25 ⁇ L of 50 mM KH 2 PO 4 , pH 4.6, 1 mM TRITON® X-IOO, 1 mg/mL Bovine Serum Albumin, and 15 ⁇ M of FRET substrate) (See Yang, et. ah, J. Neurochemistry, 91(6) 1249-59 (2004)). The content is mixed well on a plate shaker for 10 minutes.
  • Human BACEl (accession number: AF 190725) is cloned from total brain cDNA by room temperature-PCR. The nucleotide sequences corresponding to amino acid sequences #1 to 460 are inserted into the cDNA encoding human IgGi (Fc) polypeptide (Vassar et al. 1999). This fusion protein of BACEl (1-460) and human Fc, named /zwBACEl:Fc, is constructed into the pJB02 vector. Human BACEl(l-460):Fc
  • the routine whole cell assay for the measurement of inhibition of beta-secretase activity utilizes the human embryonic kidney cell line HEK293p (ATCC Accession No. CRL-1573) stably expressing a human APP751 cDNA containing the naturally occurring double mutation Lys651Met652 to Asn651Leu652, commonly called the Swedish mutation (noted HEK293/APP751sw) and shown to overproduce Abeta (Citron, et ah, Nature, 360, 672-674 (1992)).
  • HEK293/APP751sw at 3.5xlO 4 cells/well, containing 200 ⁇ L culture media, DMEM containing 10% FBS) are incubated at 37 0 C for 4 to 24 h in the presence/absence of inhibitors (diluted in DMSO) at the desired concentration.
  • conditioned media are analyzed for evidence of beta-secretase activity, for example, by analysis of Abeta peptides.
  • Total Abeta peptides (Abeta 1-x) are measured by a sandwich ELISA, using monoclonal 266 as a capture antibody and biotinylated 3D6 as reporting antibody.
  • Abeta 1-40 and Abeta 1-42 peptides are measured by a sandwich ELISA, using monoclonal 2G3 as a capture antibody for Abeta 1-40, and monoclonal 2 IF 12 as a capture antibody for Abeta 1-42.
  • Both Abeta 1-40 and Abeta 1-42 ELISAs use biotinylated 3D6 as the reporting antibody.
  • the concentration of Abeta released in the conditioned media following the compound treatment corresponds to the activity of BACEl under such conditions.
  • the 10-point inhibition curve is plotted and fitted with the four-parameter logistic equation to obtain the EC50 and IC50 values for the Abeta-lowering effect.
  • a confirmatory whole cell assay is also run in primary neuronal cultures generated from PDAPP transgenic embryonic mice.
  • Primary cortical neurons are prepared from Embryonic Day 16 PDAPP embryos and cultured in 96 well plates (15 x 10 4 cells/well in DMEM/F12 (1: 1) plus 10% FBS). After 4-6 days in vitro, culture media is replaced with serum free DMEM/F12 (1: 1) containing B27 supplement and neurons are incubated at 37 0 C for 24 h in the presence/absence of inhibitors (diluted in DMSO) at the desired concentration. At the end of the incubation, conditioned media are analyzed for evidence of beta-secretase activity, for example, by analysis of Abeta peptides.
  • Total Abeta peptides are measured by a sandwich ELISA, using monoclonal 266 as a capture antibody and biotinylated 3D6 as reporting antibody.
  • Abeta 1-40 and Abeta 1-42 peptides are measured by a sandwich ELISA, using monoclonal 2G3 as a capture antibody for Abeta 1-40, and monoclonal 2 IF 12 as a capture antibody for Abeta 1-42.
  • Both Abeta 1-40 and Abeta 1-42 ELISAs use biotinylated 3D6 as the reporting antibody.
  • the concentration of Abeta released in the conditioned media following the compound treatment corresponds to the activity of BACEl under such conditions.
  • the 10-point inhibition curve is plotted and fitted with the four-parameter logistic equation to obtain the EC50 and IC50 values for the Abeta-lowering effect.
  • the following exemplified compounds were tested essentially as described above and exhibited the following activity for Abeta lowering effect:
  • Beta-Secretase Several animal models, including mouse, guinea pig, dog, and monkey, may be used to screen for inhibition of beta- secretase activity in vivo following compound treatment.
  • Animals used in this invention can be wild type, transgenic, or gene knockout animals.
  • the PDAPP mouse model prepared as described in Games et al., Nature 373, 523-527 (1995), and other non-transgenic or gene knockout animals are useful to analyze in vivo inhibition of Abeta and sAPPbeta production in the presence of inhibitory compounds.
  • mice 2 to 12 month old PDAPP mice, gene knockout mice or non-transgenic animals are administered compound formulated in vehicles, such as corn oil, cyclodextran, phosphate buffers, PHARMASOLVE®, or other suitable vehicles.
  • vehicles such as corn oil, cyclodextran, phosphate buffers, PHARMASOLVE®, or other suitable vehicles.
  • animals are sacrificed, and brains as well as cerebrospinal fluid and plasma are removed for analysis of Abetas, C99, and sAPP fragments.
  • PHARMASOLVE® phosphate buffers
  • sAPP fragments See Dovey, et al, Journal ofNeurochemistry, 76, 173-181 (2001); and Johnson- Wood, et al, Proc. Natl Acad. Sci. USA, 94, 1550-1555 (1997)).
  • mice are dosed with various concentrations of compound and compared to a vehicle-treated control group dosed at the same time.
  • brain tissue, plasma, or cerebrospinal fluid is obtained from selected animals, beginning at time 0 to establish a baseline. Compound is administered to other groups and sacrificed at various times after dosing.
  • Brain tissue, plasma, or cerebrospinal fluid is obtained from selected animals and analyzed for the presence of APP cleavage products, including Abeta peptides, sAPPbeta, and other APP fragments, for example, by specific sandwich ELISA assays.
  • mice are sacrificed and brain tissues, plasma, or cerebrospinal fluid are analyzed for the presence of Abeta peptides, C99, and sAPPbeta, as appropriate. Brain tissues of APP transgenic animals are also analyzed for the amount of beta-amyloid plaques following compound treatment.
  • Animals (PDAPP or other APP transgenic or non-trans genie mice) administered an inhibitory compound may demonstrate the reduction of Abeta or sAPPbeta in brain tissues, plasma or cerebrospinal fluids and decrease of beta amyloid plaques in brain tissue, as compared with vehicle-treated controls or time zero controls. For example, 3 hours after administration of 10 mg/kg subcutaneous dose of the compound of Example 1 to young female PDAPP mice, Abeta 1 -x peptide, C99 and sAPPb levels are reduced approximately 64%, 60%, and 44% in brain cortex, respectively, compared to vehicle- treated mice.
  • CSF sAPPbeta levels are reduced 22%, while CSF sAPPalpha levels are unchanged 3 hours after oral administration of a 10 mg/kg dose of the compound of Example 1.
  • the compounds of the present invention are preferably formulated as
  • compositions administered by a variety of routes are for oral administration.
  • Such pharmaceutical compositions and processes for preparing same are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy (A. Gennaro, et. ah, eds., 19 th ed., Mack Publishing Co., 1995).
  • the compounds of Formula I are generally effective over a wide dosage range.
  • dosages per day normally fall within the range of about 0.01 to about 30 mg/kg of body weight. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

The present invention provides BACE inhibitors of Formula I: methods for their use, intermediates, and methods for their preparation.

Description

BACE INHIBITORS
The present invention is in the field of treatment of Alzheimer's disease and other diseases and disorders involving amyloid β (Aβ) peptide, a neurotoxic and highly aggregatory peptide segment of amyloid precursor protein (APP). Complete or partial inhibition of β-secretase or β-site amyloid precursor protein-cleaving enzyme (BACE) has been shown to have a significant effect on plaque-related and plaque-dependent pathologies in mouse models suggesting that even small reductions in Aβ levels might result in long-term significant reduction in plaque burden and synaptic deficits, thus providing significant therapeutic benefits.
Currently described BACE inhibitors are peptidomimetic transition state analogs, typically containing a hydroxy ethyl moiety. Although many of these compounds are potent inhibitors of BACE, their high molecular weights and low membrane permeability make them poor drug candidates. See Park and Lee, Journal of the American Chemical Society, 125(52), 16416-16422 (2003). There has been a progression from large peptidomimetic molecules to small molecules, such as a variety of hydroxy ethylamine scaffolds as well as heterocyclic-containing scaffolds. See e.g., Durham and Shepherd, Current Opinion in Drug Discovery & Development, 9(6), 776-791 (2006). Certain aminothiazine compounds have been described as BACE inhibitors in WO 2007/049532, WO 2008/133273, and WO 2008/133274.
BACE inhibitors that are potent and more efficacious are necessary to provide treatments for Aβ peptide-mediated disorders, such as Alzheimer's disease. The present invention provides new potent and efficacious inhibitors of BACE.
The present invention provides compounds of Formula I:
Figure imgf000003_0001
wherein:
X is -CH2- or -O-;
n is 0 or 1 ;
m is 0, 1, or 2;
p is 0 or 1 ; p must be 0 when X is -O-;
R1 is -NHCOR4, pyrimidinyl, pyridinyl optionally substituted with halo or phenyl optionally monosubstituted with -C1-C3 alkoxy;
R2 is halo;
R3 is -Ci -C3 alkoxy, hydroxy, or -0-CH2-O-CH3; and
R4 is phenyl, pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl;
or a pharmaceutically acceptable salt thereof.
The present invention also provides a method of treating Alzheimer's disease in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention.
The present invention further provides a method of preventing the progression of mild cognitive impairment to Alzheimer's disease in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof..
The present invention further provides a method of preventing the progression in a patient at risk for developing Alzheimer's disease comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof..
The present invention also provides a method of inhibiting BACE in a patient comprising administering to a mammal in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof..
The present invention also provides a method for inhibiting BACE-mediated cleavage of amyloid precursor protein comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
The present invention further provides a method for the inhibition of production of Aβ peptide comprising administering to a patient in need of such treatment an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.
The present invention also provides a pharmaceutical formulation comprising a compound of the invention or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent, or excipient. In a particular embodiment, the formulation further comprises one or more other therapeutic agents.
Furthermore, this invention provides a compound of the invention or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment of Alzheimer's disease or for the prevention of the progression of mild cognitive impairment to Alzheimer's disease. Even furthermore, this invention provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Alzheimer's disease. This invention also provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention of the progression of mild cognitive impairment to Alzheimer's disease. The invention also provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of BACE. The invention further provides the use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the inhibition of production of Aβ peptide.
Additionally, this invention provides a pharmaceutical formulation adapted for the treatment of Alzheimer's disease. Furthermore, this invention provides a pharmaceutical formulation adapted for the prevention of the progression of mild cognitive impairment to Alzheimer's disease. This invention also provides a pharmaceutical formulation adapted for the inhibition of BACE.
Furthermore the present invention provides a pharmaceutical formulation adapted for the inhibition of BACE-mediated cleavage of amyloid precursor protein. The present invention also provides a pharmaceutical formulation adapted for the treatment of conditions resulting from excessive levels of Aβ peptide comprising a compound of the -A-
invention or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, carriers, or diluents.
The general chemical terms used in the formulae above have their usual meanings.
For example, the term "-C1-C3 alkoxy" is a -C1-C3 alkyl group bonded to an oxygen atom and refers to methoxy, ethoxy, propoxy, and ώo-propoxy. However, "halo" refers to fluoro and chloro.
The term "nitrogen protecting group" is taken to mean a moiety that is stable to projected reaction conditions and yet may be selectively removed by reagents and reaction conditions compatible with the regenerated amine. Such groups are well known by the skilled artisan and are described in the literature. See, e.g., Greene and Wuts,
Protective Groups in Organic Synthesis, Third Edition, Chapter 7, John Wiley and Sons
Inc., (1999).
The term "inhibition of production of Aβ peptide" is taken to mean decreasing of in vivo levels of Aβ peptide in a mammal.
The term "effective amount of a compound of Formula I" is taken to mean the dose or doses of a compound of the invention required to inhibit BACE sufficiently to decrease in vivo levels of Aβ peptide in a mammal.
Mild cognitive impairment has been defined as a potential prodromal phase of dementia associated with Alzheimer's disease based on clinical presentation and on progression of patients exhibiting mild cognitive impairment to Alzheimer's dementia over time. (Morris, et ah, Arch. Neurol., 58, 397-405 (2001); Petersen, et ah, Arch.
Neurol., 56, 303-308 (1999)). The term "prevention of the progression of mild cognitive impairment to Alzheimer's disease" includes slowing, arresting, or reversing the progression of mild cognitive impairment to Alzheimer's disease in a patient.
The skilled artisan will appreciate that compounds of the invention can exist in tautomeric forms, as depicted in Figure (1). When any reference in this application to one of the specific tautomers of the compounds of the invention is given, it is understood to encompass both tautomeric forms and all mixtures thereof.
Figure imgf000007_0001
Figure (1)
The skilled artisan will appreciate that compounds of the invention are comprised of a core that contains at least two chiral centers:
Figure imgf000007_0002
Figure (2)
Although the present invention contemplates all individual enantiomers, as well as mixtures of the enantiomers of said compounds including racemates, the compounds with the absolute configuration at the atoms labeled 1 and 2 as illustrated in Figure (2) are preferred compounds of the invention.
Additionally, the skilled artisan will appreciate that additional chiral centers may be created in the compounds of the invention by the selection of certain variables. The present invention contemplates all individual enantiomers or diastereomers, as well as mixtures of the enantiomers and diastereomers of said compounds including racemates.
The skilled artisan will also appreciate that the Cahn-Ingold-Prelog (R) or (S) designations for all chiral centers will vary depending upon the substitution patterns of the particular compound. The single enantiomers or diastereomers may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques. Alternatively, the single enantiomers or diastereomers may be isolated from mixtures by standard chiral chromatographic or crystallization techniques at any convenient point in the synthesis of compounds of the invention. Single enantiomers and diastereomers of compounds of the invention are a preferred embodiment of the invention.
The compounds of the present invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al. Handbook of Pharmaceutical Salts: Properties, Selection and Use, (VCHA/Wiley-VCH, 2002); S.M. Berge, et al, "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977. Preferred pharmaceutically acceptable salts are those formed with hydrochloric acid.
Although all of the compounds of the invention are useful inhibitors of BACE, certain classes of compounds are preferred. The following paragraphs describe such preferred classes:
a) n is 0;
b) n is 1;
c) m is 0;
d) m is 1;
e) m is 2;
f) p is O;
g) p is 1;
h) p must be 0 when X is -O-;
i) X is -O-;
j) X iS -CH2-;
k) R1 Is -NHCOR4;
1) R1 is pyridinyl;
m) R1 is pyridinyl optionally substituted with -Cl and -F;
n) R1 is pyrimidinyl;
o) R1 is pyrimidinyl or pyridinyl optionally substituted with halo;
p) R1 is -NHCOR4, pyrimidinyl, or pyridinyl optionally substituted with -Cl and
-F; q) R1 is -NHCOR4, phenyl optionally substituted with -C1-C3 alkoxy, pyrimidinyl, or pyridinyl optionally substituted with -Cl and -F; r) R1 is -NHCOR4, phenyl optionally substituted with -C1-C3 alkoxy, or
pyrimidinyl;
s) R1 is -NHCOR4 or pyrimidinyl;
t) R2 is fluoro;
u) R3 is -C1-C3 alkoxy or hydroxy;
v) R3 is -OCH3, -OCH2(CHs)2, or hydroxy;
w) R4 is phenyl
x) R4 is thiazolyl;
y) R4 is pyridinyl optionally substituted with -Cl or -F, pyrimidinyl optionally substituted with halo, or pyrizinyl;
z) R4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally
substituted with halo, or thiazolyl;
aa) R4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally
substituted with halo, pyrizinyl, or thiazolyl;
bb) R4 is pyridinyl optionally substituted with halo or pyrimidinyl optionally substituted with halo;
cc) R4 is pyridinyl;
dd) R4 is pyridinyl optionally substituted with halo;
ee) R4 is pyridinyl optionally substituted with fluoro;
ff) The compound of the invention has a cis configuration at the chiral centers at the junction of the fused aminothiazine ring;
gg) The compound of the invention is a free base;
hh) The compound of the invention is a pharmaceutically acceptable salt;
ii) The compound of the invention is the hydrochloride salt,
jj) The compound of the invention is the dihydrochloride salt.
kk) The compound of the invention is the ethanesulfonate salt.
11) The compound of the invention is thep-toluenesulfonate salt.
A preferred embodiment of the compounds of the present invention relates to compounds of the invention, wherein X is -CH2- or -0-; n is O or 1; m is O, 1, or 2; p is 0 or 1 ; p must be 0 when X is -O-;RX is -NHCOR4, pyrimidinyl, or pyridinyl optionally substituted with halo; R2 is fluoro; R3 is -C1-C3 alkoxy or hydroxy; R4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl; or a pharmaceutically acceptable salt thereof. In said embodiment, halo is chloro or fluoro when R4 is pyridinyl or chloro when R4 is pyrimidinyl. Furthermore, in said embodiment, it is preferred that the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
Another preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH2- or -O-; n is 0 or 1 ; m is 0 or 1 ; p is 1 ; p must be 0 when X is -O-;RX is -NHCOR4, phenyl optionally substituted with -C1-C3 alkoxy, pyrimidinyl, or pyridinyl optionally substituted with halo; R is fluoro; R is -C1- C3 alkoxy or hydroxy; R4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, or thiazolyl; or a pharmaceutically acceptable salt thereof. In said embodiment, halo is chloro or fluoro when R4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof. Furthermore, in said embodiment, it is preferred that the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
A more preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH2- or -O-; n is 0 or 1; m is 0, 1, or 2; p is 0 or 1; p must be 0 when X is -O-;RX is -NHCOR4 or pyrimidinyl; R2 is fluoro; R3 is -C1- C3 alkoxy or hydroxy; R4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl; or a pharmaceutically acceptable salt thereof. In said embodiment, halo is chloro or fluoro when R4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof. Furthermore, in said embodiment, it is preferred that the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
A further embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH2- or -O-; n is 0 or 1; m is 0 or 1; p is 0 or 1; p must be 0 when X is -O-;RX is -NHCOR4, phenyl optionally substituted with -C1-C3 alkoxy, or pyrimidinyl; R2 is fluoro; R3 is -C1-C3 alkoxy or hydroxy; R4 is pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl; or a pharmaceutically acceptable salt thereof. In said embodiment, halo is chloro or fluoro when R4 is pyridinyl or pyrimidinyl. Furthermore, in said embodiment, it is preferred that the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
A most preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH2- or -O-; n is 0 or 1; m is 0 or 1; p is 0 or 1; p must be 0 when X is -O-;RX is -NHCOR4 or pyrimidinyl; R2 is fluoro; R3 is -C1-C3 alkoxy or hydroxy; R4 is pyridinyl optionally substituted with halo, or pyrimidinyl optionally substituted with halo; or a pharmaceutically acceptable salt thereof. In said embodiment, halo is chloro or fluoro when R4 is pyridinyl or pyrimidinyl; or a pharmaceutically acceptable salt thereof. Furthermore, in said embodiment, it is preferred that the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
Another most preferred embodiment of the compounds of the present invention relates to compounds of Formula I, wherein X is -CH2- or -O-; n is 0 or 1; m is 0 or 1; p is 0; R1 is -NHCOR4; R2 is fluoro; R4 is pyridinyl optionally substituted with halo; or a pharmaceutically acceptable salt thereof. In said embodiment, halo is chloro or fluoro when R4 is pyridinyl; or a pharmaceutically acceptable salt thereof. Furthermore, in said embodiment, it is preferred that the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
An especially preferred embodiment of the compounds of the present invention relates to compounds of Formula I wherein X is -O-; n is 0; m is 1; p is 0; R1 is
-NHCOR4; R2 is halo; R4 is pyridinyl substituted with halo; or a pharmaceutically acceptable salt thereof. In said embodiment, it is preferred that R is fluoro; or a pharmaceutically acceptable salt thereof. Further, in said embodiment, it is preferred that the compounds possess a cis configuration at the chiral centers at the junction of the fused aminothiazine ring; or a pharmaceutically acceptable salt thereof.
A further especially preferred embodiment of the compounds of the present invention relating to compounds of Formula I is
Figure imgf000012_0001
; or a pharmaceutically acceptable salt thereof. Another especially preferred embodiment of the compounds of the present invention relating to compounds of Formula I is
Figure imgf000012_0002
; or a pharmaceutically acceptable salt thereof. The compounds of Formula I are inhibitors of BACE. Thus, the present invention also provides a method of inhibiting BACE in a mammal that comprises administering to a mammal in need of said treatment a BACE-inhibiting amount of a compound of Formula I. It is preferred that the mammal to be treated by the administration of the compounds of Formula I is human.
As inhibitors of BACE, the compounds of the present invention are useful for suppressing the production of Aβ peptide, and therefore for the treatment of disorders resulting from excessive Aβ peptide levels due to over-production and/or reduced clearance of Aβ peptide. A further embodiment of the present invention is the use of a compound of Formula I for the manufacture of a medicament for treating a disease or condition capable of being improved or prevented by inhibition of BACE. The compounds of Formula I are therefore believed to be useful in treating or preventing Alzheimer's disease, mild cognitive impairment, Down's Syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, other degenerative dementias such as: dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated cortical basal degeneration, and diffuse Lewy body type of Alzheimer's disease. The compounds of the present invention, or salts thereof, may be prepared by a variety of procedures known in the art, some of which are illustrated in the Schemes, Preparations, and Examples below. The specific synthetic steps for each of the routes described may be combined in different ways, or in conjunction with steps from different schemes, to prepare compounds of Formula I, or salts thereof. The products of each step in the schemes below can be recovered by conventional methods, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization.
Certain stereochemical centers have been left unspecified and certain substituents have been eliminated in the following schemes for the sake of clarity and are not intended to limit the teaching of the schemes in any way. Furthermore, individual isomers, enantiomers, or diastereomers may be separated at any convenient point in the synthesis of compounds of Formula I by methods such as chiral chromatography. Additionally, the intermediates described in the following schemes contain a number of nitrogen protecting groups. The variable protecting group may be the same or different in each occurrence depending on the particular reaction conditions and the particular transformations to be performed. The protection and deprotection conditions are well known to the skilled artisan and are described in the literature. See. e.g., Greene and Wuts, Protective Groups in Organic Synthesis, supra.
The abbreviations used herein are defined according to Aldrichimica Acta, Vol. 17, No. 1, 1984. Other abbreviations are defined as follows: "Prep" refers to preparation; "Ex" refers to example; "min" refers to minute or minutes; "ACN" refers to acetonitrile; "DIPEA" refers to diisopropylethylamine; "DIC" refers to diisopropylcarbodiimide; "Et2O" refers to diethyl ether; "EtOAc" refers to ethyl acetate; "HATU" refers to 2-(1H- 7-azabenzotriazol- 1 -yl)~ 1,1,3,3 -tetramethyl uronium hexafluorophosphate
methanaminium "ΗBTU" refers to O-benzotriazole-N,N,N',N'-tetramethyl-uronium- hexafluoro-phosphate; "ΗOAt" refers to l-hydroxy-7-azabenzotriazole; "iPrOΗ" refers to isopropanol; "MeOH" refers to methyl alcohol or methanol; "(OEt)" refers to ethoxide; "PyBOP" refers to benzotriazol-1-yloxytripyrrolidino-phosphonium
hexafluorophosphate; "PyBrop" refers to bromo-tris-pyrrolidino phosphoniumhexafluoro phosphate; "DMAP" refers to 4-dimethylaminopyridine; "PPI13" refers to
triphenylphosphine; "TFA" refers to trifluoroacetic acid; "TΗF" refers to tetrahydrofuran; "EtOH" refers to ethyl alcohol or ethanol; "SCX" refers to strong cation exchange; "TR" refers to retention time; "IC50" refers to the concentration of an agent that produces 50% of the maximal inhibitory response possible for that agent; "APP" refers to amyloid precursor protein; "DMEM" refers to Dulbecco's Modified Eagle's Medium; "F12" refers to Ham's F12 medium; "FBS" refers to Fetal Bovine Serum; "FRET" refers to fluorescence resonance energy transfer; "HEK" refers to human embryonic kidney "PDAPP" refers to platelet derived amyloid precursor protein; and "RFU" refers to relative fluorescence unit.
In the schemes below, all substituents unless otherwise indicated, are as previously defined. The reagents and starting materials are generally readily available to one of ordinary skill in the art. Others may be made by standard techniques of organic and heterocyclic chemistry which are analogous to the syntheses of known structurally- similar compounds and the procedures described in the Preparations and Examples which follow including any novel procedures.
Scheme I
Figure imgf000014_0001
(1) (3) (I)
Scheme I depicts the acylation of an appropriate amine compound of formula (1) with an aryl carboxylic acid of formula (2) to give a compound of formula (I) after the deprotection of the intermediate (3). "PG" is a protecting group developed for the amino group, such as carbamates and amides. Such protecting groups are well known and appreciated in the art.
A compound of formula (1) is reacted with a compound of formula (2) under coupling conditions. One skilled in the art will recognize that there are a number of methods and reagents for amide formation resulting from the reaction of carboxylic acids and amines. For example, the reaction of an appropriate compound of formula (1) with an appropriate acid of formula (2) in the presence of a coupling reagent and an amine base, such as DIPEA or triethylamine, will give a compound of formula (3). Coupling reagents include carbodiimides, such as DCC, DIC, EDCI, and aromatic coupling reagents, such as HOBt and HOAt. Additionally, uronium or phosphonium salts of non- nucleophilic anions, such as HBTU, HATU, PyBOP, and PyBrOP can be used in place of the more traditional coupling reagents. Additives such as DMAP may be used to enhance the reactions. Alternatively, a compound of formula (1) can be acylated using substituted benzoyl chlorides in the presence of a base, such as triethylamine or pyridine.
The protecting group in intermediate (3) can be removed under acidic or basic conditions to give the compounds of formula (1). The deprotection of such compounds is well known and appreciated in the art.
In an optional step, a pharmaceutically acceptable salt of a compound of Formula (I) can be formed by reaction of an appropriate free base of Formula (I) with an appropriate pharmaceutically acceptable acid in a suitable solvent under standard conditions. Additionally, the formation of such salts can occur simultaneously upon deprotection of a nitrogen protecting group. The formation of such salts is well known and appreciated in the art.
Scheme II
Deprotection
Figure imgf000015_0001
Figure imgf000015_0002
Scheme II depicts the alkylation of an appropriate compound of formula (4) with an aryl boronic acid (5) to give a compound of formula I after deprotection of the intermediate (6). Y is trifluoromethanesulfonyl or a halogen, such as Br or I. R1 is an aryl group, such as phenyl, or a heteroaryl group, such as pyridinyl.
For example, an appropriate compound of formula (4) is reacted with an appropriate boronic acid (6) under Suzuki-Miyaura cross coupling conditions. The skilled artisan will recognize that there are a variety of conditions useful for facilitating such cross-coupling reactions. Accordingly, a suitable palladium reagent includes bis(triphenylphosphine)palladium(II) chloride, tris(dibenzylideneacetone)dipalladium (O) with tricyclohexylphosphine, (1,1 '-bis(diphenylphosphino)ferrocene)palladium(II) chloride, palladium tetrakistriphenylphosphine, or palladium(II) acetate. A suitable base includes cesium carbonate, sodium carbonate, potassium carbonate, or potassium phosphate tribasic monohydrate.
The protecting group can be removed under acidic or basic conditions to give bi- aryl compounds of formula I. The deprotection of such compounds is well known and appreciated in the art.
Scheme III
Figure imgf000016_0001
Scheme III depicts two variations to prepare the primary amine (1) starting from an appropriate aryl bromide (7).
In one variation, azido-dehalogenation is performed on the appropriate aryl bromide (7) in the presence of an azide source, such as sodium azide. Such azido- dehalogenation reactions are well known and appreciated in the art. Reduction of the resulting azide (8) to the primary amine (1) may be effected by using a number of reducing agents well known in the art, such as LiAlH4, NaBH4, PPI13, or via
hydrogenation conditions that are well known and described in the art.
Alternatively, the appropriate primary amine (1) can be prepared directly by reacting an appropriate aryl bromide (7) with an ammonia surrogate, such as trifluoroacetamide in the presence of a catalyst, such as copper iodide, a base, such as potassium carbonate, and a ligand, such as (+/-) trans N,N'-dimethyl 1,2- cyclohexanediamine. Such reactions are well known and appreciated in the art.
As will be readily appreciated, compounds of formula (7) can be promptly prepared by methods similar to those described herein by procedures that are well-known and established in the art. As will be readily understood, the steps to prepare the compounds of formula I are dependent upon the particular compound being synthesized, the starting compound, and the relative lability of the substituted moieties.
Preparations and Examples
The following preparations and examples further illustrate the invention.
The names for the compounds of the present invention are provided by
ChemDraw® Ultra, version 10.0.
The mass spectrometry data, unless specified otherwise, is obtained via LC/MS: Phenomenex Gemini C18 (2.0 x 50 μm, 3.5μm) column at a temperature of 50 0C +/- 10 0C with a flow rate of 1 mL/min. The elution system is 5 to 100% ACΝ w/ 0.1% ammonium hydroxide for 7.0 minutes then held at 100% ACΝ for 1.0 minute coupled with electrospray ionization (100-800 amu scan range; 0.2 amu step; 80v Fragmentor; 1.0 gain; 80 threshold).
The gas chromatography data unless specified otherwise is obtained via GC/MS: Agilent gas chromatography DB-5ms (0.25 mm x 15 m x 0.25 μm) with a temperature program of 60 - 280 0C in 7.3 minutes then held at 280 0C for 2.0 minutes and a split ratio of 20:1.
Preparation 1
tert-Butyl 2-(allyloxy)acetate
I O°
' ^0'
Tetrabutylammonium hydrogenosulfate (470 g, 1.40 mol) is added to a solution of sodium hydroxide (6.6 Kg, 165 mol) in water (14 L) and toluene (14 L) at 20 0C. AHyI alcohol (801.5 g, 13.8 mol) is added and the mixture is stirred at 20 0C for Ih. The mixture is cooled to 5 0C, and tert-butyl 2-bromoacetate (4 Kg, 20.5 mol) is added slowly maintaining the internal temperature below 15 0C. The reaction mixture is stirred at room temperature for 16 h. The mixture is diluted with water (12 L) and hexanes (12 L) and the organic phase is separated. The aqueous phase is extracted with MTBE (5 L). The combined organic phase is dried over magnesium sulfate, filtered, and concentrated to afford the title compound as colorless oil (2.6 Kg, 100%). ES/MS m/e: 173 (M+ 1). Preparation 2
2-(Allyloxy) acetic acid
O
HO'
Tert-butyl 2-(allyloxy)acetate (2.6 Kg, 15.1 mol) is added to dichloromethane (14 L). 4 M HCl in dioxane (14 L) is added in one portion and the solution is stirred at 25 0C for 16 h. The solvent is removed under reduced pressure and the residue is dried under vacuum at room temperature to afford the title compound (2.2 Kg, 100%). ES/MS m/e: 117 (M+l).
Preparation 3
2-(Allyloxy)-N-methoxy-N-methylacetamide
Figure imgf000018_0001
Thionyl chloride (1.5 L) is added in one portion to a solution of 2-(allyloxy) acetic acid (2.2 Kg, 18.9 mol) in toluene (3.0 L), and the mixture is heated at 65 0C under a nitrogen atmosphere for Ih. The mixture is cooled to room temperature and is added to a solution of Ν,O-dimethylhydroxylamine hydrochloride (2.1 Kg, 21.5 mol) and N-methyl morpholine (6.5 L, 59.2 mol) in dichloromethane (19 L) at 5 0C. The reaction mixture is stirred at 25 0C for 16 h. Water is added, and the reaction mixture is extracted with dichloromethane. The combined organic phase is collected and washed with 1 M HCl (6 L), dried over magnesium sulfate and concentrated under reduced pressure. The residue is purified by silica gel chromatography eluting with ethyl acetate in hexanes to afford the title compound (1.49 Kg, 50%). ES/MS m/e: 160 (M+l).
Preparation 4
2-(Allyloxy)-l-(5-bromo-2-fluorophenyl)ethanone
Figure imgf000019_0001
To a stirred -72 0C solution of 4-bromo-l-fluoro-2-iodobenzene (130.4 g, 433.5 mmol) in tetrahydrofuran (722 mL) is added 2.5 M butyl lithium in hexane (173.4 mL, 433.5 mmol) under a nitrogen atmosphere over 40 min. The reaction is stirred for 30 minutes at -72 0C and 2-(allyloxy)-N-methoxy-N-methylacetamide (57.5 g, 361.2 mmol) in tetrahydrofuran (115 mL) is added dropwise for 35 minutes. After 45 min at -72 0C, the cooling bath is removed and mixture is warmed to 25 0C. The reaction is quenched with saturated aqueous NH4Cl (500 mL), diluted with water (300 mL) and extracted three times with ethyl acetate. Organics are combined, dried over magnesium sulfate, filtered, and the solvent is removed under reduced pressure. The residue is purified by silica gel chromatography using a linear gradient of 5% to 10% ethyl acetate in hexanes to give the title compound (63 g, 64%). ES/MS m/e (79Br/81Br) 273/275 (M+l).
The following compounds in Table 1 are prepared essentially as described in the preparation of 2-(allyloxy)-l-(5-bromo-2-fluorophenyl)ethanone.
Table 1
Figure imgf000019_0002
1 H NMR (400 MHz, CDCl3): 8.06 (t, J = 1.6 Hz, IH), 7.86-7.84 (m, IH), 7.71- 7.68 (m,lH), 7.34 (t, J =7.9 Hz, IH), 5.98-5.91 (m, IH), 5.34-5.23 (m, 2H), 4.69 (s, 2H), 4.14-4.11 (m, 2H).
2 Diethyl ether is utilized instead of THF as the reaction solvent.
3 3: 1 Toluene:hexane is utilized instead of THF as the reaction solvent.
Compounds are recovered as a mixture
Preparation 5
2-(Allyloxy)-l-(5-bromo-2-fluorophenyl)ethanone oxime
Figure imgf000020_0001
To a solution of 2-(allyloxy)-l-(5-bromo-2-fluorophenyl)ethanone (118 g, 432.1 mmol) in ethanol (1.7 L) is added hydroxylamine hydrochloride (34.5 g, 496.9 mmol) and sodium ethanoate (40.8 g, 496.9 mmol) at 25 0C. The reaction is heated at 70 0C for 1 hr. The reaction is cooled and the solvent is removed under reduced pressure. The residue is washed with water (1 L) and is extracted three times with dichloromethane (3 X 500 mL). The organic phase is dried over magnesium sulfate, filtered, and the solvent is removed under reduced pressure, to obtain the title compound as a mixture of two possible oximes (120 g, 96%). ES/MS m/e (7W1Br) 288, 290 (M+l).
The following compounds in Table 2 are prepared essentially as described in the preparation of 2-(allyloxy)-l-(5-bromo-2-fluorophenyl)ethanone oxime.
Table 2
Figure imgf000020_0002
4 Compounds are recovered as a mixture. Preparation 6
Racemic (3aSR,6aSR)-6a-(5-Bromo-2-fluorophenyl)hexahydrofuro[3,4-c]isoxazole
Figure imgf000021_0001
A solution of 2-(allyloxy)-l-(5-bromo-2-fluorophenyl)ethanone oxime (120 g, 417 mmol) in xylene (2 L) is heated at 140 0C for 6 h. The reaction is cooled and the solvent is removed under reduced pressure to give a solid. The solid is purified by trituration with 9: 1 hexanes/MTBE to give the title compound (85 g, 72%). ES/MS m/e (79Br/81Br) 288, 290 (M+l).
The following compounds in Table 3 are prepared essentially as described in the preparation of racemic (3aSR,6aSR)-6a-(5-bromo-2-fluorophenyl)hexahydrofuro[3,4- c]isoxazole.
Table 3
Figure imgf000021_0003
5 This reaction is performed in toluene for 18 hours at 150 0C in a sealed tube. 6 Compounds are recovered as a mixture.
Preparation 7
Racemic ((3RS,4SR)-4-Amino-4-(5-bromo-2-fluorophenyl)tetrahydrofuran-3- yl)methanol
Figure imgf000021_0002
Zinc powder (190 g, 2.91 mol) is added to a mixture of racemic (3aSR,6aSR)-6a- (5-bromo-2-fluorophenyl)hexahydrofuro[3,4-c]isoxazole (84 g, 290 mmol) in acetic acid (1.4 L) at a rate maintaining the temperature below 30 0C. The reaction is heated at 40 0C for 5 h. The reaction is cooled to room temperature and is filtered through a pad of diatomaceous earth, washed with acetic acid and water (200 mL). The solvent is removed under reduced pressure. Water (500 mL) is added to the residue, and the pH is adjusted to pH 10 with 2 M aqueous sodium hydroxide. The basic aqueous suspension is extracted three times with 15% isopropyl alcohol in dichloromethane (3X 500 mL). The combined organic layer is dried over magnesium sulfate and the solvent is removed under reduced pressure to give the title compound as a white solid (73.0 g, 86%). ES/MS m/e
(79Br/81Br) 290, 292 (M+l).
The following compounds in Table 4 are prepared essentially as described in the preparation of racemic ((3RS,4SR)-4-amino-4-(5-bromo-2-fluorophenyl)tetrahydrofuran- 3-yl)methanol.
Table 4
Figure imgf000022_0001
7 20 equivalents of zinc dust are used in 0.06 M acetic acid, Compounds are recovered as a mixture.
Preparation 8
Racemic N-((3SR,4RS)-3-(5-Bromo-2-fluorophenyl)-4-(hydroxymethyl)tetrahydrofuran-
3 -ylcarbamothioyl)benzamide
Figure imgf000023_0001
To a solution of racemic ((3RS,4SR)-4-amino-4-(5-bromo-2- fluorophenyl)tetrahydrofuran-3-yl)methanol (75 g, 259 mmol) in tetrahydrofuran (1.3 L) at 25 0C under a nitrogen atmosphere is added dropwise
bis(trimethylsilyl)trifluoroacetamide (76.3 mL, 259 mmol) keeping the internal temperature below 30 0C. The reaction is stirred at 25 0C for 30 minutes. Benzoyl isothiocyanate (38.4 mL, 284 mmol) is added over 10 minutes keeping internal temperature below 35 0C and the reaction is stirred at 25 0C for 30 min. The reaction mixture is diluted with ethyl acetate (500 mL) and is washed three times with 1 N HCl (3 X 500 mL), followed by water and brine. The solution is dried over magnesium sulfate and the solvent is removed under reduced pressure. The residue is purified by silica gel chromatography using a linear gradient of 25% to 50% ethyl acetate in hexanes to give the title compound (110 g, 94%). ES/MS m/e (79Br/81Br) 453, 455 (M+ 1).
The following compounds in Table 5 are prepared essentially as described in the preparation of racemic N-((3SR,4RS)-3-(5-bromo-2-fluorop
henyl)-4-(hydroxymethyl)tetrahydrofuran-3-ylcarbamothioyl)benzamide.
Table 5
Figure imgf000023_0002
Figure imgf000024_0002
8 Compounds are recovered as a mixture.
Preparation 9
Racemic N-((4aSR,7aS
R)-7a-(5-Bromo-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2- yl)benzamide
Figure imgf000024_0001
To a 15 0C mixture of racemic N-((3SR,4RS)-3-(5-bromo-2-fluorophenyl)-4- (hydroxymethyl)tetrahydrofuran-3-ylcarbamothioyl)benzamide (110 g, 243 mmol) and triphenylphosphine (76.4 g, 291 mmol) in tetrahydrofuran (970 mL) is added di-tert-butyl azodicarboxylate (67.1 g, 291 mmol) in 3 portions over 10 minutes keeping internal temperature below 25 0C. After the addition, the reaction mixture is stirred at 25 0C for 1 hour. The solvent is removed under reduced pressure and the residue is purified by silica gel chromatography using a linear gradient of 14% to 33% ethyl acetate in hexanes to give the title compound (80 g, 76%). ES/MS m/e (79Br/81Br) 435, 437 (M+l).
The following compounds in Table 6 are prepared essentially as described in the preparation of racemic N-((4aSR,7aSR)-7a-(5-bromo-2-fluorophenyl)-4a,5,7,7a- tetrahydro-4Η-furo[3,4-d][l,3]thiazin-2-yl)benzamide.
Table 6
Figure imgf000024_0003
Figure imgf000025_0002
9 Purified by radial chromatography eluting with 10% to 15% ethyl acetate in
hexane.
10 Compounds are recovered as a mixture.
Preparation 10
N-((4aS, 7aS>7a-(5-Bromo-2-fluorophenyl)-4a,5,7Ja-tetrahydro-4H-furo[3 ,4-d\ [ 1 ,3 ] thiazin-2 -y l)benzamide
Figure imgf000025_0001
Racemic N-((4aSR,7aSR)- (7a(5-bromo-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-(/][l,3]thiazin-2-yl)benzamide (108 g, 248 mmol) is purified by chiral ΗPLC: Chiralcel OJ-Η 8 x 25 cm column; eluent: 90 : 10 (methanol : acetonitrile) with 0.2% dimethylethylamine; flow: 300 mL/min at UV 254 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (42.0 g, 40%). ES/MS m/e (7W1Br) 434.9/436.9 (M+ 1).
The following compounds in Table 7 are prepared essentially as described in the preparation of N-((4aS, 7a5)-7a-(5-bromo-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-ύT|[l,3] thiazin-2-yl)benzamide.
Table 7
Figure imgf000025_0003
N-((4aS,7aS)-7a-(5-Bromo-2,4-difluorophenyl)-4a,5,7,7a- (/yBr/81Br)
10c
tetrahydro-4H-furo [3 ,4-d] [ 1 ,3 ]thiazin-2-yl)benzamide 453/455
Preparation 11
Racemic (4aSR,7aSR)-7a-(5-Bromo-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d] [ 1 ,3]thiazin-2-amine
Figure imgf000026_0001
5 Ν Aqueous hydrochloric acid (158 mL) is added to N-(7a-(5-bromo-2- fluorophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2-yl)benzamide (16.35 g, 7.89 mmol) and the mixture is heated to 90 0C. After 18 hours, the mixture is allowed to cool to ambient temperature and washed with dichloromethane. The organic layer is extracted once with 5 Ν aqueous hydrochloric acid. The pΗ of the aqueous layer is adjusted to basic with 50% aqueous sodium hydroxide and is extracted twice with 10% isopropyl alcohol : dichloromethane. The organic layer is concentrated under reduced pressure. The resulting residue is purified by radial chromatography eluting with 2% to 5% 7 Ν ammonia in methanol: dichloromethane to give the title compound (2.23g, 47%). ES/MS m/e (7W1Br) 331, 333 (M+l).
The following compounds in Table 8 are prepared essentially by the method of racemic (4aSR,7aSR)-7a-(5-bromo-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d] [ 1 ,3]thiazin-2-amine.
Table 8
Figure imgf000026_0002
11 Compounds are recovered as a mixture. Preparation 12
N-((4aS,7aS)-7a-(5-Amino-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-2-yl)benzamide
Figure imgf000027_0001
To a 2 L round bottom flask is added N-((4aS, 7a5)-7a-(5-bromo-2-fluorophenyl)-
4a,5,7,7a-tetrahydro-4H-fiiro[3,4-uT|[l,3] thiazin-2-yl)benzamide (35.0 g, 80.4 mmol), trifluoroacetamide (16.2 g, 143 mmol), copper(I) iodide (2.66 g, 13.7 mmol), sodium iodide (21.3 g, 141 mmol) and potassium carbonate (21.5 g, 153 mmol). The flask is capped with a septum, vacuum and back filled with nitrogen. 1,4-dioxane (731 mL) (previously degassed with vacuum-nitrogen) is added via cannula, and N,N'-dimethyl-, trans (+/-) 1 ,2-cyclohexanediamine (10.1 g, 70.8 mmol) is added. The mixture is placed in a preheated oil bath at 100 0C and stirred at this temperature for 19 h. The septum is replaced by a reflux condenser and a mixture of methanol (154 mL) and water (154 mL) is added through the condenser. The mixture is stirred at 100 0C for 3.5 h, cooled to 22 0C, and concentrated partially under reduced pressure (to 0.6 L volume). Aqueous ammonium hydroxide (25%, 154 mL) is added and the mixture is stirred for 10 min. The mixture is extracted three times with ethyl acetate (3 X 500 mL) and the solvent is removed under reduced pressure. A residue is obtained that is purified by flash chromatography with a linear gradient of 50% to 75% ethyl acetate in hexane to give the title compound (14.9 g, 47%). ES/MS m/e: 372 (M+l).
Preparation 13
N-((4aS,7aS)-7a-(3-Azidophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2- yl)benzamide
Figure imgf000027_0002
A 0.66 M solution of L-ascorbic acid is prepared by dissolving L-ascorbic acid sodium salt (0.79 g, 2.0 mmol) in water (6 mL). N-((4aS,7aS)-7a-(3-bromophenyl)- 4a,5,7,7a-tetrahydro-4H-fiiro[3,4-d][l,3]thiazin-2-yl)benzamide (1.40 g, 3.35 mmol) and 1,2-cyclohexanediamine, N,N'-dimethyl-, trans (+/-) (162 mg, 1.11 mmol) are dissolved in ethanol (13.4 mL). Sodium azide (0.661 g, 10.1 mmol) is added. The 0.66 M aqueous L-ascorbic acid sodium salt (2.24 mL) and water (2.58 mL) are added. The reaction flask is fitted with a reflux condenser and the mixture is degassed and evacuated with nitrogen. Copper (II) sulfate pentahydrate (0.184 g, 0.738 mmol) is added and the reaction flask is heated to 80 0C and stirred for 1.5 h. The reaction mixture is cooled to room temperature and ice water is added. The reaction mixture is extracted three times with ethyl acetate. The combined organic phase is dried over sodium sulfate and the solvent is removed under reduced pressure to give a residue that is purified on silica gel with 50% ethyl acetate in hexanes to give the title compound (0.620 g, 49%). Further elution of the flash column with 100% ethyl acetate yields more title compound (0.488 g, 41%). ES/MS m/e: 380 (M+l).
The following compounds in Table 9 are prepared essentially by the method of N- ((4aS,7aS)-7a-(3-azidophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2- yl)benzamide.
Table 9
Figure imgf000028_0002
Preparation 14
N-((4aS,7aS)-7a-(3-Aminophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2- yl)benzamide
Figure imgf000028_0001
N-((4aS,7aS)-7a-(3-azidophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin- 2-yl)benzamide (0.62 g, 1.63 mmol) is diluted with ethanol (10 mL) and Pd on carbon (10%, wet, 0.062 g). The mixture is degassed and stirred at room temperature under hydrogen (30 psi) overnight. The mixture is filtered through diatomaceous earth using ethanol as a rinse. The solvent is removed under reduced pressure to give the title compound, (0.106 g, 18%). ES/MS m/e: 354 (M+l).
The following compounds in Table 10 are prepared essentially by the method of N-((4aS,7aS)-7a-(3-aminophenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2- yl)benzamide.
Table 10
Figure imgf000029_0002
Preparation 15
N-(3-((4aS,7aS)-2-Benzamido-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-4- fluorophenyl)-5-fluoropicolinamide
Figure imgf000029_0001
A mixture ofN-((4aS,7aS)-7a-(5-amino-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-d][l,3]thiazin-2-yl)benzamide (20.4 g, 51.8 mmol), 5-fluoropicolinic acid (8.77 g, 62.2 mmol), 1-hydroxybenzotriazole hydrate (10.3 g, 67.4 mmol) and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (13.2 g, 67.4 mmol) in a mixture of dichloromethane (345 mL) and DMF (6.5 mL) is stirred at 22 0C for 80 min. A solution of 2 M sodium hydroxide (129.5 mL, 259 mmol) is added and the stirring is continued for 10 min. The mixture is separated and the aqueous phase is extracted with twice with dichloromethane (2X100 mL). The organic layer is concentrated under reduced pressure and the residue is diluted with ethyl acetate (200 mL). The organic layer is washed with cooled water (2 x 50 mL), brine (50 mL) and filtered through a short pad of silica using 100% ethyl acetate to give title compound (23.8 g, 79%). ES/MS m/e: 495 (M+ 1).
The following compounds in Table 11 are prepared essentially as described in the preparation of N-(3-((4aS,7aS)-2 -benzamido-4a,5, 7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide.
Table 11
Figure imgf000030_0002
Preparation 16
N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-4- fluorophenyl)-5-fluoropicolinamide
Figure imgf000030_0001
A solution ofN-(3-((4aS,7aS)-2-benzamido-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide (23.7 g 40.8 mmol), o-methylhydroxylamine hydrochloride (34.4 g, 412 mmol) and pyridine (33.3 mL) in ethanol (735 mL) is heated to 50 0C for 4 h. The mixture is concentrated. The residue is washed twice with methyl tert-butyl ether (2 X 250 mL) and poured into a saturated aqueous solution of sodium bicarbonate (453 mL). The suspension is shaken for 5 min and extracted with dichloromethane (1 x 1 L and 2 x 0.5 L). The organic layer is washed with water (0.5 L) dried over magnesium sulfate and the solvent is removed under reduced pressure to afford a solid. Additional solid is obtained from the aqueous phase by filtration. The solids are combined and triturated with water (300 mL) in an ultrasound bath for 30 min. The suspension is filtered off, washed with water, and dried under vacuum to give title compound (17.3 g, 100%). ES/MS m/e: 391 (M+l).
Preparation 17
1 ,5-Dibromo-2,4-difluorobenzene
Figure imgf000031_0001
Iron powder (16.49 g, 291 mmol) is added to 1 -bromo-2,4-difluorobenzene (110 mL, 968 mmol) in 1,2-dichloroethane (968 mL) in a 3 -neck flask at ambient temperature under a stream of nitrogen. A solution of bromine (59.7 mL, 1.16 mol) in
1,2-dichloroethane (968 mL) is added dropwise over 1 hour and the reaction mixture is stirred at ambient temperature for 18 h. The reaction mixture is cooled to 0 0C and a saturated aqueous solution of sodium bisulfite (1.11 L, 533 mmol) is added portionwise and the mixture is separated. The aqueous phase is extracted with dichloromethane. The organic layer is washed with a saturated aqueous solution of sodium bicarbonate, water, and brine. The organic layer is dried over sodium sulfate, and the solvent is removed under reduced pressure to give a residue purified with a pad of silica using diethyl ether to give the title compound (229 g, 76%). 1H NMR (400 MHz, CDCl3) δ 7.70 (dd, J= 4.6, 6.8 Hz, IH), 6.95-6.92 (m, IH).
Preparation 18
4-(3-Bromophenyl)tetrahydro-2H-pyran-4-ol,
Figure imgf000031_0002
To a stirred -78 0C solution of 1,3-dibromobenzene (19.71 g, 81.05 mmol) in TΗF
(150 mL) is added 1.6 M butyl lithium in hexane (50.66 mL, 81.05 mmol) and the reaction is stirred 10 minutes. 4H-Pyran-4-one, tetrahydro- (5.41 g, 54.04 mmol) is added dropwise and the reaction is stirred at -78 0C for 2 h. The reaction is quenched by addition of saturated aqueous ammonium chloride (25 mL) and is then diluted with minimal water and extracted with EtOAc. The organic layer is dried over Na2SO4 and the solvent is removed under reduced pressure to afford a residue that is purified by silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (11.18 g, 76%). GC-MS (m/e): (79Br/81Br) 256, 258 (M-I).
The following compounds in Table 12 are prepared essentially as described in the preparation of (4-(3-bromophenyl)tetrahydro-2H-pyran-4-ol.
Table 12
Figure imgf000032_0002
12 2: 1 toluene:hexanes is used as the reaction solvent.
13 Diethyl ether is used as the reaction solvent.
14 1H NMR (400 MHz, CDCl3) δ 7.64 (t, J = 2.0 Hz, IH), 7.40-7.31 (m, 2H), 7.19 (t, J = 7.9 Hz, IH), 1.99-1.82 (m, 8H).
Preparation 19
4-(3-Bromophenyl)-3,6-dihydro-2H-pyran
Figure imgf000032_0001
A mixture of 4-(3-bromophenyl)tetrahydro-2H-pyran-4-ol (11.17 g, 41.3 mmol) and p-toluenesulfonic acid monohydrate (0.797 g, 4.13 mmol) in toluene (100 mL) is heated to reflux for 30 minutes using a Dean-Stark trap to remove water. The reaction is diluted with water and 5 N NaOH and extracted with EtOAc. The organic layer is dried over Na2SO4 and the solvent is removed under reduced pressure to afford a residue that is purified on silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (8.85 g, 90%). 1H NMR (400 MHz, CDCl3) δ 2.45-2.50 (m, 2H), 3.92 (t, 2H, J = 5.71 Hz), 4.31 (q, 2H, J = 3.07 Hz, J = 5.71 Hz), 6.12-6.14 (m, IH), 7.19 (t, IH, J = 7.91 Hz), 7.28-7.32 (m, IH), 7.36-7.39 (m, IH), 7.51 (t, IH, J = 1.76 Hz).
The following compounds in Table 13 are prepared essentially as described in the preparation of 4-(3-bromophenyl)-3,6-dihydro-2H-pyran.
Table 13
Figure imgf000033_0001
15 Η NMR (400 MHz, CDCl3) δ 7.55 (t, J = 2.0 Hz, IH), 7.35-7.31 (m, IH), 7.18- 7.14 (m, 2H), 6.21-6.17 (m, IH), 2.73-2.68 (m, 2H), 2.56-2.50 (m, 2H), 2.01 (quintet, J = 7.5 Hz, 2H).
Preparation 20
(4-(3-Bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methanol
Figure imgf000034_0001
A 0 0C solution of 4-(3-bromophenyl)-3,6-dihydro-2H-pyran (0.50 g, 2.09 mmol) in CΗ2CI2 (15 mL) is treated with paraformaldehyde (0.208 g, 2.20 mmol) and stirred for 5 minutes at 0 0C. A I M solution of dimethylaluminum chloride in hexanes (3.03 mL, 3.03 mmol) is added drop-wise to the slurry. The reaction is warmed to room temperature and stirred for 1 hour. The reaction is cooled to 0 0C and more
paraformaldehyde (0.208 g, 2.20 mmol) and 1 M solution of dimethylaluminum chloride in hexanes (3.03 mL, 3.03 mmol) is added. The reaction is warmed to room temperature and stirred overnight. The reaction is quenched by pouring into an ice/1 N HCl mixture and is extracted three times with EtOAc. The combined organic layers are dried over Na2SO4 and the solvent is removed under reduced pressure to afford a residue that is purified on silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (0.315 g, 53%). 1H NMR (400 MHz, CDCl3) δ 7.50 (t, J = 2.0 Hz, IH), 7.40 (dd, J = 2.2, 7.9 Hz, IH), 7.29-7.27 (m, IH), 7.20 (t, J= 7.9 Hz, IH), 6.11 (t, J= 2.9 Hz, IH), 4.32-4.29 (m, 2H), 4.28-4.25 (m, IH), 3.76 (dd, J = 3.1, 11.4 Hz, IH), 3.70-3.64 (m, 2H), 2.70 (d, J = 2.2 Hz, IH), 1.89 (dd, J = 4.6, 6.4 Hz, IH).
The following compounds in Table 14 are prepared essentially as described in the preparation of (4-(3-bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methanol.
Table 14
Figure imgf000034_0002
2Of (2-(3-Bromophenyl)cyclopent-2-enyl)methanol NMR 18
16 1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 2.2, 6.6 Hz, IH), 7.26-7.22 (m, IH), 7.06 (t, J = 8.4 Hz, IH), 6.04 (t, J = 2.6 Hz, IH), 4.28-4.22 (m, 3H), 3.73 (dd, J = 3.1, 11.4 Hz, IH), 3.64-3.62 (m, 2H), 2.63 (d, J = 1.3 Hz, IH), 1.88 (s, IH).
17 1H NMR (400 MHz, CDCl3) δ 7.41 (t, J = 7.7 Hz, IH), 6.86 (dd, J = 8.4, 10.1 Hz, IH), 5.96 (t, J = 2.6 Hz, IH), 4.27-4.25 (m, IH), 4.15-4.06 (m, 2H), 3.83 (dd, J = 3.5, 11.4 Hz, IH), 3.61 (d, J = 4.8 Hz, 2H), 2.69-2.64 (m, IH), 1.75-1.91 (s, IH).
18 1H NMR (400 MHz, CDCl3) δ 7.53 (s, IH), 7.32 (t, J = 7.2 Hz, 2H), 7.15 (t, J = 7.9 Hz, IH), 6.19 (s, IH), 3.67 (dd, J = 3.7, 10.8 Hz, IH), 3.54 (dd, J = 6.4, 10.8 Hz, IH), 3.31 (dd, J = 1.3, 2.6 Hz, IH), 2.57-2.47 (m, 2H), 2.23-2.13 (m, IH), 2.02-2.02 (m, IH).
Preparation 21
(4-(3-Bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methyl methanesulfonate
Figure imgf000035_0001
A 0 0C solution of (4-(3-bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methanol (0.305 g,1.08 mmol) in CH2Cl2 (10 mL) is treated with triethylamine (0.218 g, 2.15 mmol) and then methanesulfonyl chloride (0.148 g, 1.29 mmol) and the reaction is stirred at 0 0C for 30 min. The reaction is diluted with water and extracted with CH2Cl2. The organic layer is dried over Na2SO4 and the solvent is removed under reduced pressure to afford the title compound (0.432 g, 97%). 1H NMR (400 MHz, CDCl3) δ 7.51 (t, J = 1.8 Hz, IH), 7.44-7.41 (m, IH), 7.31-7.29 (m, IH), 7.25-7.21 (m, IH), 6.18 (t, J = 2.6 Hz, IH), 4.33-4.31 (m, 2H), 4.20 (dd, J = 1.5, 11.6 Hz, 2H), 4.14-4.08 (m, IH), 3.72-3.68 (m, IH), 3.01-2.98 (m, IH), 2.95 (s, 3H).
The following compounds in Table 15 are prepared essentially as described in the preparation of (4-(3-bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methyl methanesulfonate. Table 15
Figure imgf000035_0002
Figure imgf000036_0002
19 Η NMR (400 MHz, CDCl3) δ 7.36 (ddd, J = 8.4, 4.4, 2.6 Hz, IH), 7.31 (dd, J = 2.6, 6.6 Hz, IH), 6.93 (dd, J = 8.8, 10.1 Hz, IH), 6.04 (t, J = 2.6 Hz, IH), 4.20- 4.31 (m, 3H), 4.08-4.03 (m, 2H), 3.80-3.76 (m, IH), 3.10 (s, IH), 2.89 (s, 3H).
20 1H NMR (400 MHz, CDCl3) δ 7.56 (dd, J = 2.2, 6.6 Hz, IH), 7.28 (ddd, J = 8.6, 4.6, 2.4 Hz, IH), 7.11 (t, J = 8.4 Hz, IH), 6.13 (t, J = 2.9 Hz, IH), 4.32-4.30 (m, 2H), 4.24 (t, J = 10.1 Hz, IH), 4.19 (dd, J = 1.3, 11.4 Hz, IH), 4.10-4.06 (m, IH), 3.68 (ddd, J = 11.6, 2.9, 1.3 Hz, IH), 2.95 (s, 4H).
21 1H NMR (400 MHz, CDCl3) δ 7.39 (t, J = 7.7 Hz, IH), 6.89 (dd, J= 8.1, 10.3 Hz, IH), 6.02 (t, J = 2.6 Hz, IH), 4.20-4.31 (m, 3H), 4.08-4.02 (m, 2H), 3.81-3.75 (m, IH), 2.92 (s, 4H).
22 1H NMR (400 MHz, CDCl3) δ 7.42-7.44 (m, IH), 7.36-3.39 (m, IH), 7.18-7.22 (m, 2H), 6.08-6.11 (m, IH), 4.00-4.03 (m, 2H), 3.08-3.13 (brd, IH), 2.85 (s, 3H), 2.18-2.22 (m, 2H), 1.94-2.01 (m, IH), 1.78-1.88 (m, IH), 1.63-1.71 (m, 2H).
23 DMAP and triethylamine is utilized in this reaction.
24 1H NMR (400 MHz, CDCl3) δ 7.53 (s, IH), 7.37-7.29 (m, 2H), 7.19 (t, J = 7.9 Hz, IH), 6.22 (s, IH), 4.26 (dd, J = 4.0, 10.1 Hz, IH), 4.01 (dd, J = 7.9, 9.7 Hz, IH), 3.54-3.52 (m, IH), 2.86 (s, 3H), 2.59-2.51 (m, 2H), 2.28-2.19 (m, IH), 2.04 (ddd, J = 17.0, 7.8, 3.8 Hz, IH).
Preparation 22
(4-(3-Bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methyl carbamimidothioate
methanesulfonate
Figure imgf000036_0001
A mixture of (4-(3-bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methyl
methanesulfonate (4.82 g, 11.7 mmol) and thiourea (1.78 g, 23.3 mmol) in isopropyl alcohol (100 mL) is heated to reflux for 24 h. The reaction is cooled and the solvent is removed under reduced vacuum to give a residue that is combined with acetonitrile (30 mL) and hexanes (10 mL). A solid crystallizes and the slurry is cooled to 0 0C. The slurry is filtered using 3 : 1 ACN : hexanes as a rinse (25 mL) to give the title compound as the mesylate salt (3.45 g, 70%). ES/MS m/e (79Br/81Br) 327, 329 (M+l). The following compounds in Table 16 are prepared essentially as described in the preparation of (4-(3-bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methyl
carbamimidothioate methanesulfonate.
Table 16
Figure imgf000037_0002
Preparation 23
Racemic (4aSR,8aSR)-8a-(3-Bromophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3- d] [ 1 ,3]thiazin-2-amine
Figure imgf000037_0001
A mixture of (4-(3-bromophenyl)-3,6-dihydro-2H-pyran-3-yl)methyl carbamimidothioate methanesulfonate (3.41 g, 8.05 mmol) in methanesulfonic acid (35 mL) is heated at 50 0C for 5 h. The reaction is cooled and added to ice water. The mixture is diluted with EtOAc and the pΗ adjusted with 5 N NaOH to basic. The basic aqueous layer is extracted three times with ethyl acetate and the organic layer is dried over Na2SO4. The solvent is removed under reduced pressure. The resulting residue is triturated with CH2Cl2 to give the title racemic compound. Additional racemic product is obtained by purification of the filtrate by silica gel chromatography eluting with a linear gradient of 1% to 10% 7 M NH3MeOH in CH2Cl2 (1.99 g, 76%). ES/MS m/e (79Br/81Br) 327, 329 (M+l).
The following compounds in Table 17 are prepared essentially as described in the preparation of (4aSR,8aSR)-8a-(3-bromophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3- d][l,3]thiazin-2-amine.
Table 17
Figure imgf000038_0002
25 The reaction is heated at 90 0C overnight.
26 The reaction is heated at 50 0C for 5 h.
27 The reaction is stirred at room temperature for 3 h.
28 The reaction is stirred at room temperature for 17 h. Product isolated as the salt.
Preparation 24
Racemic tert-Butyl (4aSR,8aSR)-8a-(3-bromophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate
Figure imgf000038_0001
A mixture of racemic (4aSR,8aSR)-8a-(3-bromophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-amine (2.08 g, 6.36 mmol) and di-t- butyldicarbonate (2.77 g, 12.7 mmol) in 1,4-dioxane (60 mL) and saturated aqueous NaHCO3 (60 mL) is stirred at room temperature for 8 h. The mixture is diluted water and extracted three times with EtOAc. The combined organic layers are dried over Na2SO4 and the solvent is removed under reduced pressure to afford material that is purified by silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (2.81 g, 100 %). ES/MS m/e (79Br/81Br) 427, 429 (M+l).
The following compounds in Table 18 are prepared essentially as described in the preparation of racemic tert-butyl (4aSR,8aSR)-8a-(3-bromophenyl)-4,4a,5, 7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate.
Table 18
Figure imgf000039_0002
Preparation 25
tert-Butyl (8aS)-8a-(3-bromophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3-d][l,3]thiazin-
2-ylcarbamate,
Figure imgf000039_0001
Racemic tert-butyl (4aSR,8aSR)-8a-(3-bromophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (2.80 g, 6.55 mmol) is purified by chiral HP LC: Column: Chiralcel OJ 8 x 35 cm; eluent: 75 : 25 (methanol : acetonitrile); flow: 400 mL/min at UV 260 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (1.31 g, 47%). ES/MS m/e (79Br/81Br) 427, 429 (M+l).
The following compounds in Table 19 are prepared essentially as described in the preparation of tert-butyl (8aS)-8a-(3-bromophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3- d][l,3]thiazin-2-ylcarbamate.
Table 19
Figure imgf000040_0002
Preparation 26
tert-Butyl (8aS)-8a-(3-azidophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3-d][l,3]thiazin-2- ylcarbamate
Figure imgf000040_0001
A 0.33 M solution of copper sulfate is prepared by dissolving copper (II) sulfate pentahydrate (1.0 g, 2.0 mmol) in water (12 mL). A 0.66 M solution of L-ascorbic acid is prepared by dissolving L-ascorbic acid sodium salt (1.58 g, 4.0 mmol) in water (12 mL). To a solution of tert-butyl (8aS)-8a-(3-bromophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (0.500 g, 1.20 mmol) in ethanol (3.6 mL) is added sodium azide (0.228 g, 3.50 mmol), 1,2-cyclohexanediamine, N,N -dimethyl-, trans (+/-) (0.0549 g, 0.386 mmol), 0.66 M aqueous L-ascorbic acid sodium salt (0.772 mL, 0.509 mmol), and water (0.71 mL) and the mixture is purged with nitrogen. A 0.33 M aqueous solution of copper (II) sulfate pentahydrate (0.773 mL, 0.255 mmol) is added and the reaction is heated to 80 0C for 12 min. The reaction is poured into cold water to afford a blue mixture that is extracted three times with
EtOAc. The organic layer is dried over Na2SO4 to afford crude material which is purified by silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (0.400 g, 88 %). ES/MS m/e: 390 (M+l).
The following compounds in Table 20 are prepared essentially as described in the preparation of tert-butyl (8aS)-8a-(3-azidophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3- d] [ 1 ,3 ]thiazin-2-ylcarbamate.
Table 20
Figure imgf000041_0002
Preparation 27
tert-Butyl (8aS)-8a-(3-aminophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3-d][l,3]thiazin-2- ylcarbamate
Figure imgf000041_0001
A mixture of tert-butyl (8aS)-8a-(3-azidophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (0.398 g, 1.02 mmol) and palladium on carbon -10% by weight (0.200 g) in ethanol (25 mL) is purged with nitrogen then hydrogen. The reaction is stirred at room temperature under hydrogen (30 psi) for 2 h. Na2SO4 is added to the reaction mixture and it is filtered through diatomaceous earth, using methanol to rinse the filter cake. The solvent is removed under reduced pressure to give the title compound (0.361 g, 97%). ES/MS m/e: 364 (M+l).
The following compounds in Table 21 are prepared essentially as described in the preparation of tert-butyl (8aS)-8a-(3-aminophenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3- d] [ 1 ,3 ]thiazin-2-ylcarbamate.
Table 21
Figure imgf000042_0002
Preparation 28
tert-Butyl (8aS)-8a-(3-(5-chloropicolinamido)phenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate
Figure imgf000042_0001
To a mixture of tert-butyl (8aS)-8a-(3-aminophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (0.15 g, 0.413 mmol), 5- chloropyridine-2-carboxylic acid (0.078 g, 0.495 mmol) and 1-hydroxybenzotriazole (0.073 g, 0.536 mmol) in CH2Cl2 (2.75 mL) and DMF (0.3 mL) is added l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.103 g, 0.536 mmol). The reaction is stirred overnight at room temperature. The reaction mixture is diluted with water, 5 N NaOH (0.5 mL) and extracted three times with CH2Cl2. The combined organic layer is dried over Na2SO4 and the crude product is purified by silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (0.176 g, 85 %). ES/MS m/e: (35C1/37C1) 503, 505 (M+ 1).
The following compounds in Table 22 are prepared essentially as described in the preparation of tert-butyl (8aS)-8a-(3-(5-chloropicolinamido)phenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate.
Table 22
Figure imgf000043_0001
Figure imgf000044_0002
Preparation 29
tert-Butyl (4aS,7aS)-7a-(2-fluoro-5-(5-fluoropicolinamido)phenyl)-4a,5,7,7a-tetrahydro- 4H-furo[3 ,4-d] [ 1 ,3 ]thiazin-2-ylcarbamate
Figure imgf000044_0001
Racemic tert-butyl (4aSR,7aSR)-7a-(2-fluoro-5-(5-fluoropicolinamido)phenyl)- 4a,5,7,7a-tetrahydro-4H-fiiro[3,4-d][l,3]thiazin-2-ylcarbamate (0.226 g, 0.460 mmol) is purified by chiral ΗPLC: 2.1 x 25 cm Chiralcel OD-Η, 5 micron column, 30% methanol/CO2, flow rate: 70 mL/min, UV: 230 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (0.092 g, 41%). ES/MS (m/e): 491 (M+l).
The following compounds in Table 23 are prepared essentially by the method of tert-butyl (4aS,7aS)-7a-(2-fluoro-5-(5-fluoropicolinamido)phenyl)-4a,5,7,7a-tetrahydro- 4H-furo[3,4-d][l,3]thiazin-2-ylcarbamate.
Table 23
Figure imgf000044_0003
tert-Butyl (4aS,7aS)-7a-(2-fluoro-5-(5-fluoropyrimidine-2-
29b carboxamido)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- 492
d] [ 1 ,3]thiazin-2-ylcarbamate
Preparation 30
tert-Butyl (8aS)-8a-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate
Figure imgf000045_0001
A mixture of tert-butyl 8a-(5-bromo-2,4-difluorophenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (0.300 g, 0.647 mmol) in 1,2- dimethoxy ethane (10 mL), ethanol (4 mL) and water (5 mL) is purged with nitrogen and heated to 97 0C. Pyrimidine-5-boronic acid (0.655 g, 5.18 mmol), cesium carbonate (1.90g, 5.83 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.09 Ig, 0.129 mmol) is added in a single portion and the reaction is heated at 97 0C for 20 minutes. The reaction is cooled, diluted with water, and extracted with EtOAc. The organic layer is dried over Na2SO4 and the crude product is purified by silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (0.258 g, 86 %). ES/MS (m/e): 463 (M + 1).
The following compound in Table 24 are prepared essentially as described in the preparation of tert-butyl (8aS)-8a-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4,4a,5,7,8,8a- hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate.
Table 24
Figure imgf000045_0002
29 Compounds are recovered as a mixture. Preparation 31
Racemic (4aSR,7aSR)-7a-(4-Fluoro-3-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-d] [ 1 ,3 ]thiazin-2 -amine and
Racemic (4aSR,7aSR)-7a-(2-Fluoro-5-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-d][l,3]thiazin-2-amine
Figure imgf000046_0001
A solution of 4 M Hydrogen chloride in dioxane (19.2 mL) is added to a mixture of racemic tert-butyl (4aSR,7aSR)-7a-(4-fluoro-3-(pyrimidin-5-yl)phenyl)-4a,5,7,7a- tetrahydro-4H-furo[3,4-d][l,3]thiazin-2-ylcarbamate and racemic tert-butyl (4aSR,7aSR)- 7a-(2-fluoro-5-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin- 2-ylcarbamate (1.80 g, 0.962 mmol) and the reaction is stirred at room temperature for 3 h. The mixture is diluted with aqueous 1 N HCl and is extracted with
dichloromethane. Aqueous 5 N sodium hydroxide is added to the aqueous layer to make it basic and it is extracted twice with 10% isopropyl alcohol in dichloromethane. The solvent is removed under reduced pressure to give a residue that is purified on silica gel using radial chromatography eluting with 3% to 10% 2M ammonia in methanol :
dichloromethane. The material is purified again using radial chromatography eluting with 10% isopropylamine : 30% ethyl acetate : 60% hexane to give the title compounds as a racemic two component mixture (0.231 g, 73%). ES/MS m/e: 331 (M+l).
Preparation 32
(4aS,7aS)-7a-(4-Fluoro-3-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-2-amine and
(4aS,7aS)-7a-(2-Fluoro-5-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d] [ 1 ,3]thiazin-2-amine
Figure imgf000047_0001
The mixture of racemic (4aSR,7aSR)-7a-(4-fluoro-3-(pyrimidin-5-yl)phenyl)- 4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2-amine and racemic (4aSR,7aSR)-7a-(2- fluoro-5-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-2- amine (0.231 g, 0.697 mmol) are separated using a Chiralpak AD-Η 3 x 25 cm column eluting with 3/2 EtOH : acetonitrile with 0.2% dimethylethylamine at a flow rate of 30 mL/min., 225 nM to give (4aS,7aS)-7a-(4-fluoro-3-(pyrimidin-5-yl)phenyl)-4a,5,7,7a- tetrahydro-4H-furo[3,4-d][l,3]thiazin-2-amine (TR= 3.12 )(0.032 g, 14%): ES/MS m/e: 331 (M+ 1) and (4aS,7aS)-7a-(2-fluoro-5-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro- 4Η-furo[3,4-d][l,3]thiazin-2-amine (TR= 4.479 )(0.058 g, 25%). ES/MS m/e: 331 (M+l).
Preparation 33
(7aS)-7a-(4-Fluoro-3-methoxyphenyl)-4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-
2 -amine
Figure imgf000047_0002
To a solution tert-butyl 7 a-(4-fluoro-3-methoxyphenyl)-4,4a,5, 6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-ylcarbamate (1.04 g, 2.73 mmol) in CH2CI2 (20 mL) is added TFA (5 mL) and the reaction is stirred at room temperature for 16 hr. The solvent is removed under reduced pressure to give a residue that is diluted with water and 5N NaOH. The aqueous layer is extracted four times with EtOAc. The organic layer is dried over Na2SO4 and the solvent is removed under reduced pressure. The crude product is purified with a 10 g SCX column using 4 : 1 CH2Cl2 : MeOH and then 2 : 1 CH2Cl2 : 7 N NH3 in MeOH to elute the product and give the title compound (0.756 g, 99%). ES/MS m/e: 281 (M+l).
Preparation 34
5-((7aS)-2-Amino-4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-7a-yl)-2- fluorophenol
Figure imgf000048_0001
To a -78 0C solution of (7aS)-7a-(4-fluoro-3-methoxyphenyl)-4,4a,5, 6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-amine (0.717 g, 2.56 mmol) in CH2CI2 (15 mL) is added boron tribromide 11.20 g, 7.67 mmol). The reaction is warmed to 0 0C and is stirred for 2 hr. The reaction is diluted with water and the pH is adjusted to 7. The aqueous is extracted three times with EtOAc (some MeOH is added to help dissolve some solids during the extraction). The organic layer is dried over Na2SO4 and the solvent is removed under reduced pressure. The crude product is purified with a 10 g SCX column using 4 : 1 CH2Cl2 : MeOH and then 2 : 1 CH2Cl2 : 7 N NH3 in MeOH to elute the product and give the title compound (0.56 g, 82%). ES/MS m/e: 267 (M + 1).
Preparation 35
tert-Butyl (7aS)-7a-(4-fluoro-3-hydroxyphenyl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-ylcarbamate
Figure imgf000048_0002
To a mixture of 5-((4aR,7aS)-2-amino-4,4a,5,6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-7a-yl)-2-fluorophenol (0.524 g, 1.97 mmol) in 1,4- dioxane (20 mL) and saturated aqueous NaHCO3 (20 mL) is added a solution of di-tert- butyldicarbonate (0.451 g, 2.07 mmol) in 1,4-dioxane (2 mL). The mixture is stirred at room temperature for 16 h. The mixture is diluted water and extracted three times with EtOAc. The organic layer is dried over Na2SO4 and the crude product is purified by silica gel chromatography eluting with a linear gradient of 5% to 100% EtOAc in hexanes to give the title compound (0.436 g, 61%). ES/MS m/e: 367 (M+l).
Preparation 36
5-((7aS)-2-(tert-Butoxycarbonylamino)-4,4a,5, 6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-7a-yl)-2-fluorophenyl trifluoromethanesulfonate,
Figure imgf000049_0001
To a 0 0C mixture of tert-butyl (4aR,7aS)-7a-(4-fluoro-3-hydroxyphenyl)-
4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-ylcarbamate (0.428 g, 1.17 mmol) and pyridine (0.148 g, 1.87 mmol) in dichloromethane (25 mL) is added
trifluoromethanesulfonic anhydride (0.395 g, 1.40 mmol). The reaction is stirred at 0 0C for 45 min. The reaction is diluted with water and 1 N HCl (4 mL) and is extracted three times with CH2Cl2. The organic layer is dried over Na2SO4 and the solvent is removed under reduced pressure to give the title compound (0.633 g, 100%). ES/MS m/e: 499 (M+l).
Preparation 37
5-Bromo-2,4-difluorobenzaldehyde
A 1.6 M solution of butyl lithium in hexane (114 mL, 182 mmol) is added to a -78
0C solution of l,5-dibromo-2,4-difluorobenzene (41.3 g, 152 mmol) in diethyl ether (290 mL). Dimethylformamide (14.4 g, 198 mmol) is added and the reaction is stirred at -78 0C for 15 minutes. The reaction is quenched with 1 N HCl (300 mL), is diluted with water, and extracted three times with ethyl acetate. The organic layer is dried over sodium sulfate and the solvent is removed under reduced pressure to give crude material that is purified by silica gel chromatography with a linear gradient of 0% to 50% CH2Cl2 in hexanes over 30 minutes to give the title compound (20.51 g, 61%). GC-MS m/e
(79Br/81Br) 220, 222.
Preparation 38
1 -(3 -Bromophenyl)but-3 -en- 1 -ol
Figure imgf000050_0001
To a solution of 3-bromobenzaldehyde (15.8 g, 85.6 mmol) in dry diethyl ether (200 mL) at 0 0C under nitrogen atmosphere with stirring is added allylmagnesium bromide solution in ether (85.6 mL, 85.6 mmol) dropwise. The resulting mixture is warmed to room temperature over 1 hr and is quenched by the addition of 1 N HCl aqueous solution. The reaction is extracted with dichloromethane, washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with 0% to 100%
dichloromethane in hexanes over 50 minutes to give the title compound as a racemic mixture (17.01 g, 88%). ES/MS m/e (79Br/81Br) 227, 229 (M+l).
The following compounds in Table 25 are prepared essentially as described in the preparation of l-(3-bromophenyl)but-3-en-l-ol.
Table 25
Figure imgf000050_0002
Preparation 39
(l-(3-Bromophenyl)but-3-enyloxy)(tert-butyl)dimethylsilane
Figure imgf000051_0001
A solution of l-(3-bromophenyl)but-3-en-l-ol (17.0 g, 74.9 mmol), lH-imidazole (11.8 g, 172.2 mmol) and tert-butyldimethylchlorosilane (13.9 g, 89.8 mmol) in DMF (40 mL) is stirred at room temperature for 2 hours. The mixture is diluted with
dichloromethane and is washed sequentially with water and saturated ammonium chloride aqueous solution. The organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The crude product is purified by silica gel chromatography eluting with 5% ethyl acetate in hexanes to give the title compound as racemic mixture (23.9 g, 94%). 1H NMR (400 MHz, CDCl3) δ 7.44 (s, IH), 7.34 (d, IH, J= 7.5 Hz), 7.24-7.14 (m, 2H), 5.78-5.70 (m, IH), 5.02-4.97 (m, 2H), 4.65- 4.62 (m, IH), 2.45-2.31 (m, 2H), 0.87 (s, 9H), 0.02 (s, 3H), 0.12 (s, 3H).
The following compounds in Table 26 are prepared essentially as described in the preparation of (l-(3-bromophenyl)but-3-enyloxy)(tert-butyl)dimethylsilane.
Table 26
Figure imgf000051_0002
30 1H NMR (400 MHz, CDCl3) δ 7.48-7.46 (m, IH), 7.24-7.16 (m, IH), 7.03 (t,lH, J = 8.5 Hz), 5.76-5.67 (m, IH), 5.02-4.96 (m, 2H), 4.64-4.61 (m, IH), 2.43-2.31 (m, 2H), 0.87 (s, 9H), 0.02 (s, 3H), -0.13 (s, 3H).
31 1H NMR (400 MHz, CDCl3) δ 7.63 (t, J = 7.7 Hz, IH), 6.78 (dd, J = 8.4, 9.6 Hz, IH), 5.76-5.68 (m, IH), 5.01-4.95 (m, 3H), 2.36 (t, J= 6.5 Hz, 2H), 0.86 (s, 9H), 0.03 (s, 3H), -0.11 (s, 3H).
Preparation 40
3-(3-Bromophenyl)-3-(tert-butyldimethylsilyloxy)propanal
Figure imgf000052_0001
A solution of (l-(3-bromophenyl)but-3-enyloxy)(tert-butyl)dimethylsilane (23.9 g, 70.1 mmol) dichloromethane (120 mL) is cooled to -78 0C under nitrogen atmosphere. Ozone is then bubbled through the solution until it becomes blue. The mixture is flushed with nitrogen. Triethylamine (14.2 g, 140.2 mmol) is added to the solution. The mixture is warmed to room temperature and stirred for 4 hours. The mixture is concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with a linear gradient of 0% to 8% ethyl acetate in hexanes over 25 minutes to give the title compound as a racemic mixture (17.9 g, 74%): 1H NMR (400 MHz, CDCl3) δ 9.75-9.74 (m, IH), 7.48 (d, IH, J= 1.8 Hz), 7.38-7.36 (m, IH), 7.25-7.23 (m, IH), 7.18 (t, IH, J= 7.7 Hz), 5.15 (dd, IH, J= 4.0, 7.9 Hz), 2.81 (ddd, IH, J= 15.9, 8.0, 2.5 Hz), 2.63-2.57 (m, IH), 0.84-0.83 (m, 9H), 0.02-0.02 (m, 3H), -0.14 (s, 3H).
The following compounds in Table 27 are prepared essentially as described in the preparation of 3-(3-bromophenyl)-3-(tert-butyldimethylsilyloxy)propanal.
Table 27
Figure imgf000052_0002
32 H NMR (400 MHz, CDCl3) δ 9.74 (t, IH, J = 2.0 Hz), 7.52 (dd, IH, J = 2.1, 6.6 Hz), 7.25-7.21 (m, IH), 7.06 (t, IH, J = 8.4 Hz), 5.15 (dd, IH, J = 4.3, 7.9 Hz), 2.81 (ddd, IH, J = 16.1, 7.9, 2.4 Hz), 2.60 (ddd, IH, J = 16.1, 4.3, 1.8 Hz), 0.84 (s, 9H), 0.03 (s, 3H), -0.14 (s, 3H).
33 1H NMR (400 MHz, CDCl3) δ 9.74 (dd, J = 1.9, 2.5 Hz, IH), 7.68-7.64 (m, IH), 6.83 (dd, J = 8.2, 9.7 Hz, IH), 5.43 (ddd, J = 7.9, 3.9, 0.5 Hz, IH), 2.78 (ddd, J = 16.1, 7.9, 2.7 Hz, IH), 2.62 (ddd, J = 16.1, 3.9, 1.7 Hz, IH), 0.85 (s, 9H), 0.05 (s, 3H), -0.11 (s, 3H).
Preparation 41
1 -(3 -Bromophenyl)- 1 -(tert-butyldimethylsilyloxy)hex-5 -en-3 -ol
Figure imgf000053_0001
To a 0 0C solution of 3-(3-bromophenyl)-3-(tert-butyldimethylsilyloxy)propanal (17.9 g, 52.1 mmol) in dry diethyl ether (150 mL) is added 1 M allylmagnesium bromide solution in ether (52.1 mL, 52.1 mmol). The resulting mixture is warmed to room temperature over 1 hour. The mixture is diluted with dichloromethane and is quenched by addition of saturated aqueous solution of ammonium chloride. The mixture is extracted three times with dichloromethane. The combined organic layers are washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound as a racemic diastereomeric mixture (18.8 g, 84%). 1H NMR (400 MHz, CDCl3) δ 7.45 (s, IH), 7.38-7.34 (m, IH), 7.24-7.21 (m, IH), 7.19-7.15 (m, IH), 5.84-5.76 (m, IH), 5.09-5.04 (m, IH), 5.00 (t, J= 5.3 Hz, IH), 4.86-4.80 (m, IH), 3.83-3.75 (m, 2H), 2.23-2.15 (m, 2H), 1.80-1.69 (m, 2H), 0.89 (d, 9H, J= 6.6 Hz), 0.06- 0.04 (m, 3H), -0.17 (d, J= 40.4 Hz, 3H).
The following compounds in Table 28 are prepared essentially as described in the preparation of l-(3-bromophenyl)-l-(tert-butyldimethylsilyloxy)hex-5-en-3-ol.
Table 28
Figure imgf000053_0002
34 1H NMR (400 MHz, CDCl3) δ 7.49 (dt, J = 6.6, 2.0 Hz, IH), 7.23-7.20 (m, IH), 7.05 (t, J = 8.4 Hz, IH), 5.82-5.76 (m, IH), 5.09-5.04 (m, IH), 4.98 (t, J = 5.3 Hz, IH), 4.88-4.82 (m, IH), 3.83-3.74 (m, 2H), 3.05-2.22-2.15 (m, 2H), 1.85-1.71 (m, 2H), 0.88-0.87 (m, 9H), 0.05-0.04 (m, 3H), -0.17 (d, J = 34.4 Hz, 3H).
35 1H NMR (400 MHz, CDCl3) δ 7.68-7.60 (m, IH), 6.83-6.78 (m, IH), 5.82-5.76 (m, IH), 5.28-5.24 (m, 0.5H), 5.13-5.09 (m, 0.5H), 5.09-5.05 (m, 2H), 3.82-3.79 (m, IH), 2.96 (d, J = 1.9 Hz, 0.5H), 2.59 (d, J = 3.2 Hz, 0.5H), 2.22-2.19 (m, 2H), 1.83-1.73 (m, 2H), 0.88 (s, 4.5H), 0.87 (s, 4.5H), 0.06 (s, 1.5H), 0.06 (s, 1.5H), - 0.11 (s, 1.5H), -0.19 (s, 1.5H). Preparation 42
1 -(3 -Bromophenyl)hex-5 -ene- 1 ,3 -diol
Figure imgf000054_0001
To a solution of l-(3-bromophenyl)-l-(tert-butyldimethylsilyloxy)hex-5-en-3-ol (18.8 g, 44.0 mmol) in tetrahydrofuran (60 mL) is added 1 M tetrabutylammonium fluoride solution in THF (66.0 mL, 66.0 mmol). The resulting mixture is stirred at room temperature for 2 hours. The mixture is diluted with dichloromethane and is washed sequentially with water and saturated ammonium chloride aqueous solution. The organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a residue. The crude product is purified by silica gel chromatography eluting with a linear gradient of 20% to 40% ethyl acetate in hexanes over 26 minutes to give the title compound as racemic diastereomeric mixture (11.8 g, 99%). 1H NMR (400 MHz, CDCl3) δ 7.52 (s, IH), 7.38-7.36 (m, IH), 7.28-7.24 (m, IH), 7.22-7.17 (m, IH), 5.83- 5.75 (m, IH), 5.15-5.11 (m, 2H), 5.03-4.89 (m, IH), 4.00-3.90 (m, IH), 2.32-2.21 (m, 2H), 1.96-1.89 (m, 2H).
The following compounds in Table 29 are prepared essentially as described in the preparation of l-(3-bromophenyl)hex-5-ene-l,3-diol.
.Table 29
Figure imgf000054_0002
36 H NMR (400 MHz, CDCl3) δ 7.56 (dt, J = 6.6, 2.0 Hz, IH), 7.26-7.22 (m, IH), 7.09-7.04 (m, IH), 5.82-5.76 (m, IH), 5.16-5.11 (m, 2H), 5.05-4.89 (m, IH), 3.99- 3.93 (m, IH), 2.32-2.27 (m, 2H), 1.89-1.78 (m, 2H).
37 1H NMR (400 MHz, CDCl3) δ 7.77-7.73 (m, IH), 6.84-6.78 (m, IH), 5.82-5.76 (m, IH), 5.27-5.15 (m, 3H), 4.07-4.02 (m, IH), 3.85-3.81 (m, 0.5H), 3.62 (d, J = 5.4 Hz, 0.5H), 2.46 (dd, J = 1.2, 2.9 Hz, 0.5H), 2.33-2.31 (m, 2.5H), 1.94-1.88 (m, IH), 1.85-1.81 (m, -IH), 1.69 (dt, J = 14.5, 10.2 Hz, IH).
Preparation 43
1 -(3 -Bromophenyl)-3 -hydroxyhex-5-en- 1 -one
Figure imgf000055_0001
A mixture of l-(3-bromophenyl)hex-5-ene-l,3-diol (2.60 g, 9.59 mmol) and manganese(IV) oxide (9.81 g, 95. 9 mmol) in dichloromethane (80 mL) is heated and stirred for 4 h under reflux. The reaction mixture is filtered through a pad of
diatomaceous earth and the residue is washed twice with dichloromethane. The filtrate is concentrated under reduced pressure to afford the title compound (2.12 g, 82%). 1H NMR (400 MHz, CDCl3) δ 8.05 (d, IH, J = 1.8 Hz), 7.85 (d, IH, J = 7.5 Hz), 7.69-7.52 (m, IH), 7.35-7.31 (m, IH), 5.91-5.82 (m, IH), 5.18-5.12 (m, 2H), 4.32-4.26 (m, IH), 3.09-3.00 (m, 2H), 2.39-2.30 (m, 2H).
The following compounds in Table 30 are prepared essentially as described in the preparation of l-(3-bromophenyl)-3-hydroxyhex-5-en-l-one.
Table 30
Figure imgf000055_0003
38 1H NMR (400 MHz, CDCl3) δ 8.16 (dd, J = 2.2, 6.6 Hz, IH), 7.89 (ddd, J = 8.6, 4.7, 2.2 Hz, IH), 7.19 (t, J = 8.3 Hz, IH), 5.91-5.83 (m, IH), 5.19-5.15 (m, 2H), 4.31-4.30 (m, IH), 3.12-2.98 (m, 2H), 2.39-2.36 (m, 2H).
39 1H NMR (400 MHz, CDCl3) δ 8.11 (t, J = 7.7 Hz, IH), 6.94 (dd, J = 8.0, 10.4 Hz, IH), 5.88-5.79 (m, IH), 5.15-5.12 (m, 2H), 4.29-4.26 (m, IH), 3.14-3.03 (m, 2H), 2.79 (d, J = 3.5 Hz, IH), 2.35-2.30 (m, 2H).
Preparation 44
l-(3-Bromophenyl)-3-(tert-butyldimethylsilyloxy)hex-5-en-l-one
Figure imgf000055_0002
A mixture of l-(3-bromophenyi)-3-hydroxyhex-5-en-l-one (9.08 g, 33.7 mmol), lH-imidazole (5.34 g, 77.6 mmol) and tert-butyldimethylchlorosilane (6.29 g, 40.5 mmol) in DMF (40 mL) is stirred at room temperature for 2 h. The mixture is diluted with dichloromethane and is washed sequentially with water and saturated ammonium chloride aqueous solution. The organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with a linear gradient of 0% to 5% ethyl acetate in hexanes over 20 minutes to give the title compound as a racemic mixture (11.3 g, 88%). ES/MS m/e (79Br/81Br) 383, 385 (M+l).
The following compounds in Table 31 are prepared essentially as described in the preparation of l-(3-bromophenyl)-3-(tert-butyldimethylsilyloxy)hex-5-en-l-one.
Table 31
Figure imgf000056_0002
40 H NMR (400 MHz, CDCl3) 5 8.16 (dd, J = 2.1, 6.6 Hz, IH), 7.89 (ddd, J = 8.6, 4.7, 2.1 Hz, IH), 7.19-7.15 (m, IH), 5.90-5.82 (m, IH), 5.12-5.07 (m, 2H), 3.15 (dd, J = 7.7, 15.3 Hz, IH), 2.82 (dd, J = 4.6, 15.3 Hz, IH), 2.38-2.33 (m, 2H), 0.88-0.78 (m, 9H), 0.04-0.01 (m, 6H).
41 1H NMR (400 MHz, CDCl3) δ 8.05-8.01 (m, IH), 6.92 (ddd, J = 10.3, 8.0, 0.3 Hz, IH), 5.85-5.78 (m, IH), 5.06 (d, J = 1.2 Hz, IH), 5.03-5.01 (m, IH), 4.40-4.35 (m, IH), 3.12-2.99 (m, 2H), 2.30-2.27 (m, 2H), 0.78 (s, 9H), 0.03 (s, 3H), -0.07 (s, 3H).
Preparation 45
1 -Benzyl-6a-(3 -bromophenyl)-5-(ter?-butyldimethylsilyloxy)hexahydro- IH- cyclopenta[c]isoxazole
To a solution of l-(3-bromophenyl)-3-(tert-butyldimethylsilyloxy)hex-5-en-l-one (6.84 g, 17.8 mmol) and N-benzylhydroxylamine (2.86 g, 23.2 mmol) in TΗF (60 mL) is added Ti(OEt)4 (8.14 g, 35.7 mmol). The reaction mixture is heated to 70 0C in a sealed tube. After 2 h, the temperature is increased to 80 0C and stirring is continued for 3 days. The reaction mixture is cooled to room temperature. Water and ethyl acetate are added and the mixture is stirred vigorously for 15 minutes. The solids are allowed to settle and the organic and aqueous layers are decanted through a pad of diatomaceous earth. The layers are separated and the aqueous layer is extracted three times with ethyl acetate. The combined organic layers are washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with 0% to 20% ethyl acetate in hexanes gradient over 20 minutes to give the title compound as a diastereomeric mixture (7.42 g, 85%). ES/MS m/e (7W1Br) 488, 490 (M+ 1).
The following compounds in Table 32 are prepared essentially as described in the preparation of 1 -benzyl-6a-(3 -bromophenyl)-5-(tert-butyldimethylsilyloxy)hexahydro- lH-cyclopenta[c]isoxazole.
Table 32
Figure imgf000057_0002
42 N-(2,4-dimethoxybenzyl)hydroxylamine utilized instead of N- benzylhydroxylamine.
43 N-(4-methoxybenzyl)hydroxylamine utilized instead of N-benzylhydroxylamine Preparation 46
1 -Benzyl-5 -(tert-butyldimethylsilyloxy)-6a-(3 '-methoxybiphenyl-3 -yl)hexahydro- 1 Η- cyclopenta[c]isoxazole
Figure imgf000057_0001
To a stirred solution of l-benzyl-6a-(3-bromophenyl)-5-(tert- butyldimethylsilyloxy)hexahydro-lH-cyclopenta[c]isoxazole (7.42 g, 15.2 mmol) in 1,2- dimethoxyethane (30 mL) is added 2 M aqueous solution of sodium carbonate (22. 8 mL, 45. 6 mmol), 3-methoxyphenylboronic acid (2.77 g, 18.2 mmol) and (1,1'- bis(diphenylphosphino)ferrocene)palladium(II) chloride (0.759 g, 0.911 mmol). The reaction mixture is heated at 110 0C for 7 hours. The reaction is cooled, diluted with ethyl acetate, and filtered. The resulting filtrate is separated and the aqueous layer is extracted three times with ethyl acetate. The combined organic layers are washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with 10% to 20% ethyl acetate in hexanes gradient over 20 minutes to give the title compound (7.59 g, 92%). ES/MS m/e: 516 (M+l).
Preparation 47
(2-Amino-4-(tert-butyldimethylsilyloxy)-2-(3'-methoxybiphenyl-3- yl)cyclopentyl)methanol
Figure imgf000058_0001
A mixture of l-benzyl-5-(ter?-butyldimethylsilyloxy)-6a-(3'-methoxybiphenyl-3- yl)hexahydro-lH-cyclopenta[c]isoxazole (2.04 g, 3.76 mmol) and palladium on carbon (0.400 g) in acetic acid (10 mL) is stirred at room temperature under hydrogen atmosphere (50 psi) for 19 hours. The reaction is filtered through a pad of diatomaceous earth and the filter cake is washed with methanol three times and the filtrate is concentrated under reduced pressure. The residue is dissolved in dichloromethane, the pΗ adjusted to pΗ 12 by addition of saturated aqueous sodium bicarbonate, and is extracted three times with dichloromethane. The combined organic layers are dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound. ES/MS m/e: 428 (M+l). Preparation 48
N-(4-(tert-Butyldimethylsilyloxy)-2-(hydroxymethyl)-l-(3'-methoxybiphenyl-3- yl)cyclopentylcarbamothioyl)benzamide
Figure imgf000059_0001
A solution of (2-amino-4-(tert-butyldimethylsilyloxy)-2-(3'-methoxybiphenyl-3- yl)cyclopentyl)methanol (9.44 g, 22.1 mmol) and benzoyl isothiocyanate (3.49 g, 21.0 mmol) in THF (88 mL) is stirred for 1.5 hours at room temperature and concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with a linear gradient of 0% to 5% methanol in dichloromethane over 27 minutes to give the title compound (9.61 g, 70%). ES/MS m/e: 589 (M-I).
Preparation 49
Racemic N-((4aRS,6RS,7aSR)-6-(tert-Butyldimethylsilyloxy)-7a-(3'-methoxybiphenyl-3- yl)-4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide
Figure imgf000059_0002
A solution of N-(4-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)-l-(3'- methoxybiphenyl-3-yl)cyclopentylcarbamothioyl)benzamide (6.37 g, 8.41 mmol) and triphenylphosphine (4.41 g, 16.8 mmol) in THF (30 mL) is added to a separate solution of di-tert-butyl azodicarboxylate (3.87 g, 16.8 mmol) in THF (15 mL) at room temperature. The reaction is stirred for 30 minutes and is concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with a linear gradient of 10% to 40% ethyl acetate in hexanes over 26 minutes to give a crude diastereomeric mixture (7.39 g, 100%). The mixture is purified again on silica gel chromatography to separate the diastereomers eluting with 15% ethyl acetate in hexanes to give the title compound as a racemic mixture (1.47 g, 24%). ES/MS m/e: 573 (M+l).
The following compound in Table 33 is prepared essentially as described in the preparation of racemic N-((4aRS,6RS,7aSR)-6-(tert-butyldimethylsilyloxy)-7a-(3'- methoxybiphenyl-3-yl)-4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2- yl)benzamide.
Table 33
Figure imgf000060_0002
Preparation 50
Racemic N-((4aRS,6RS,7aSR)-6-Hydroxy-7a-(3'-methoxybiphenyl-3-yl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Figure imgf000060_0001
To a solution of racemic N-((4aRS,6RS,7aSR)-6-(tert-butyldimethylsilyloxy)-7a- (3'-methoxybiphenyl-3-yl)-4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2- yl)benzamide (1.47 g, 2.31 mmol) in acetonitrile (6 mL) is added 20-25% aqueous fluorosilicic acid (2.82 g, 4.62 mmol) and the resulting mixture is stirred at room temperature for 3 h. The reaction is diluted with ethyl acetate and quenched with saturated aqueous sodium bicarbonate. The mixture is washed with water and brine. The organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with a linear gradient of 10% to 60% ethyl acetate in hexanes over 40 minutes to give the title compound as a racemic mixture (0.709 g, 64%). ES/MS m/e: 459 (M+l). Preparation 51
N-((4aR,6R,7aS)-6-Hydroxy-7a-(3'-methoxybiphenyl-3-yl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Figure imgf000061_0001
Racemic N-((4aRS,6RS,7aSR)-6-hydroxy-7a-(3'-methoxybiphenyl-3-yl)- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.689 g, 1.50 mmol) is purified by chiral HPLC: 2.1 x 25 cm Chiralpak AD-H, 5 micron, 35% IPA/CO2, flow rate: 70 mL/min, UV: 225 nm. The first eluting isomer is isolated to provide the enantiomerically enriched title compound (0.242 g, 35%). ES/MS m/e: 459 (M+l).
Preparation 52
N-((4aR,6R,7aS)-6-Methoxy-7a-(3'-methoxybiphenyl-3-yl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Figure imgf000061_0002
To a 0 0C mixture of N-((4aR,6R,7aS)-6-hydroxy-7a-(3'-methoxybiphenyl-3-yl)- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.086g, 0.169 mmol) and 48% aqueous fluoroboric acid (0.031 g, 0.169 mmol) in dichloromethane (0.6 mL) is added 2 M trimethylsilyldiazomethane in hexane (0.101 mL, 0.202 mmol). The mixture is stirred at 0 0C for 30 minutes and is poured into saturated aqueous solution of sodium bicarbonate. The mixture is diluted with water and is extracted with dichloromethane. The organic layer is washed sequentially with water and brine and is dried over sodium sulfate. The solvent is removed under reduced pressure and the crude product is purified by silica gel chromatography eluting with a linear gradient of 10% to 60% ethyl acetate in hexanes over 20 minutes to give the title compound (0.038 g, 48%). ES/MS m/e: 473 (M+l).
Preparation 53
N-((4aR,6R,7aS)-7a-(3'-Methoxybiphenyl-3-yl)-6-(methoxymethoxy)-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Figure imgf000062_0001
To a stirred 0 0C solution of N-((4aR,6R,7aS)-6-hydroxy-7a-(3'-methoxybiphenyl- 3-yl)-4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.087 g, 0.190 mmol) in anhydrous dichloromethane (0.6 mL) is added chloromethoxymethane (0.031 g, 0.379 mmol), followed by diisopropylethylamine (0.049 g, 0.379 mmol). The resulting mixture is stirred at 0 0C for 1 hour, and then is warmed to room temperature over 24 h. The mixture is diluted with dichloromethane, quenched by addition of saturated aqueous solution of sodium bicarbonate, and is extracted three times with dichloromethane. The combined organic layers are washed with water and brine. The organic layer is dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with a linear gradient of 0% to 60% ethyl acetate in hexanes over 26 minutes to give the title compound (0.089, 93%). ES/MS m/e: 503 (M+l).
Preparation 54
6-(tert-Butyldimethylsilyloxy)-7a-(3'-methoxybiphenyl-3-yl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-amine
Figure imgf000063_0001
A mixture of N-(6-(tert-butyldimethylsilyloxy)-7a-(3 '-methoxybiphenyl-3 -yl)- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.200 g, 0.349 mmol) and hydrazine (0.559 g, 1.75 mmol) in ethanol (4 mL) is stirred at 120 0C over night. The mixture is cooled, diluted with ethyl acetate and is washed with water. The organic layer is dried over sodium sulfate and the solvent is removed under reduced pressure to give the title compound (0.164 g, 100%). ES/MS m/e: 469 (M+l).
Preparation 55
Racemic (3aRS,5RS,6aSR)-6a-(3-Bromo-4-fluorophenyl)-l-(2,4- dimethoxybenzyl)hexahydro-lH-cyclopenta[c]isoxazol-5-ol
Figure imgf000063_0002
To a solution of 6a-(3-bromo-4-fluorophenyl)-5-(tert-butyldimethylsilyloxy)-l- (2,4-dimethoxybenzyl)hexahydro-lH-cyclopenta[c]isoxazole (3.00 g, 4.77 mmol) in TΗF (10 mL) is added 1 Ν tetrabutylammonium fluoride solution in TΗF (7.15 mL, 7.15 mmol). After stirring at room temperature for 2 hours, the reaction mixture is concentrated under reduced pressure to afford a residue that is diluted with
dichloromethane and washed with water and brine. The organic layer is dried over sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give a residue that is purified by silica gel chromatography eluting with a linear gradient of 0% to 10% methanol in dichloromethane over 20 minutes to give the title compound as a diastereomeric mixture (2.26 g, 100%). This mixture is purified again on silica gel chromatography to separate the diastereomers eluting with a linear gradient of 0% to 15% ethyl acetate in hexanes over 15 minutes to give the title compound as a racemic mixture (0.852 g, 37%). ES/MS m/e (7W1Br) 452, 454 (M+ 1).
The following compounds in Table 34 are prepared essentially as described in the preparation of racemic (3aRS,5RS,6aSR)-6a-(3-bromo-4-fluorophenyl)-l-(2,4- dimethoxybenzyl)hexahydro-lH-cyclopenta[c]isoxazol-5-ol.
Table 34
Figure imgf000064_0002
44 Isolated as a racemic mixture of diastereomers.
Preparation 56
Racemic (3aRS,5RS,6aSR)-6a-(3-Bromophenyl)-l-(2,4-dimethoxybenzyl)-5- methoxyhexahydro-lH-cyclopenta[c]isoxazole
Figure imgf000064_0001
Sodium hydride (0.076 g, 1.89 mmol) is added to a 0 0C solution of racemic (3aRS,5RS,6aSR)-6a-(3-bromophenyl)-l-(2,4-dimethoxybenzyl)hexahydro-lH- cyclopenta[c]isoxazol-5-ol (0.684 g, 1.57 mmol) in DMF (7 mL ). The reaction is warmed to room temperature for 10 minutes and then cooled to 0 0C. Methyl iodide (0.246 g, 1.73 mmol) is added and the reaction is stirred at room temperature for 6 hours. Additional sodium hydride (0.032 g, 0.790 mmol) and methyl iodide (0.112 g, 0.790 mmol) is added and the reaction is stirred at room temperature for 18 hours. The reaction is quenched with water and extracted with ethyl acetate. The organic layer is dried over sodium sulfate, filtered and the solvent is removed under reduced pressure. The resulting residue is purified by silica gel chromatography with 10% ethyl acetate in CH2Cl2 to give the title compound (0.443 g, 63 %). ES/MS m/e (79Br/81Br) 448, 450 (M+l).
The following compounds in Table 35 are prepared essentially by the method of racemic (3aRS,5RS,6aSR)-6a-(3-bromophenyl)-l-(2,4-dimethoxybenzyl)-5- methoxyhexahydro-lH-cyclopenta[c]isoxazole.
Table 35
Figure imgf000065_0002
45 Isolated as a mixture of diastereomers.
Preparation 57
Racemic (3aRS,5RS,6aSR)-6a-(3-Bromo-4-fluorophenyl)-5-isopropoxy-l-(4- methoxybenzyl)hexahydro-lH-cyclopenta[c]isoxazole
Figure imgf000065_0001
To a mixture of racemic (3aRS,5RS,6aSR)-6a-(3-bromo-4-fluorophenyl)-l-(4- methoxybenzyl)hexahydro-lH-cyclopenta[c]isoxazol-5-ol (1.72 g, 4.07 mmol) in dichloromethane (2.5 mL) is added silver trifluoromethanesulfonate (2.62 g, 10.2 mmol) and powdered dried 4A sieves (1.50 g). A solution of 2-iodopropane (1.73 g, 10.2 mmol) in dichloromethane (0.5mL) is added to the mixture over 15 minutes. The thick mixture is stirred at room temperature overnight. The mixture is diluted with dichloromethane and is filtered through diatomaceous earth. The solvent is removed under reduced pressure and the residue is purified by silica gel chromatography with a linear gradient of 0% to 10% ethyl acetate in dichloromethane over 15 minutes to give the title compound (0.466 g, 25%). ES/MS m/e (7V1Br) 464, 466 (M+l). Preparation 58
Racemic (3aRS,5RS,6aSR)-6a-(3-Bromo-4-fluorophenyl)hexahydro-lH- cyclopenta[c]isoxazol-5-ol
Figure imgf000066_0001
A mixture of racemic (3aRS,5RS,6aSR)-6a-(3-bromo-4-fluorophenyl)-l-(2,4- dimethoxybenzyl)hexahydro-lH-cyclopenta[c]isoxazol-5-ol (0.852 g, 1.79 mmol) and triethylsilane (0.624 g, 5.37 mmol) in TFA (4 mL) is heated to 80 0C for 3 h. The reaction is cooled to room temperature and concentrated under reduced pressure to afford a residue that is purified on a SCX column washing sequentially with dichloromethane, methanol and 7 N NH3 in MeOH to give the title compound as racemic mixture (0.57 g, 100%). ES/MS m/e (79Br/81Br) 302, 304 (M+ 1).
The following compounds in Table 36 are prepared essentially as described in the preparation of racemic (3aRS,5RS,6aSR)-6a-(3-bromo-4-fluorophenyl)hexahydro-lH- cyclopenta[c] isoxazol-5 -ol.
Table 36
Figure imgf000066_0002
46 Isolated as a mixture of diastereomers. Preparation 59
Racemic ( 1 RS,3 SR,4RS)-3 -Amino-3 -(3 -bromo-4-fluorophenyl)-4- (hydroxymethyl)cyclopentanol
Figure imgf000067_0001
A mixture of racemic(3aRS,5RS,6aSR)-6a-(3-bromo-4-fluorophenyl)hexahydro- lH-cyclopenta[c]isoxazol-5-ol (0.57 g, 1.89 mmol) and zinc (0.617 g, 9.43 mmol) in acetic acid (12.6 mL) is heated to 42 0C under a nitrogen atmosphere for 3 hours. The reaction is cooled to room temperature, filtered, and concentrated under reduced pressure to afford a residue that is purified on a SCX column washing sequentially with dichloromethane, methanol and 7 N NΗ3 in MeOH to give the title compound as racemic mixture (0.53 g, 92%). ES/MS m/e (7W1Br) 304, 306 (M+l).
The following compounds in Table 37 are prepared essentially as described in the preparation of racemic (lRS,3SR,4RS)-3-amino-3-(3-bromo-4-fluorophenyl)-4- (hydroxymethyl)cyclopentanol.
Table 37
Figure imgf000067_0002
47 Isolated as a mixture of diastereomers. Preparation 60
Racemic N-((lSR,2RS,4RS)-l-(3-Bromo-4-fluorophenyl)-4-hydroxy-2- (hydroxymethyl)cyclopentylcarbamothioyl)benzamide
Figure imgf000068_0001
To a solution of racemic (lRS,3SR,4RS)-3-amino-3-(3-bromo-4-fluorophenyl)-4-
(hydroxymethyl)cyclopentanol (0.48 g, 1.58 mmol) in THF (6.31 mL) is added benzoyl isothiocyanate (0.263 g, 1.58 mmol) and the mixture is stirred at room temperature for 1.5 h. The solvent is removed under reduced pressure and the crude product is purified by silica gel chromatography, eluting with a linear gradient of 0% to 10% methanol in dichloromethane over 20 minutes to give the title compound as racemic mixture (0.602 g, 76%). ES/MS m/e (79Br/81Br) 467, 469 (M+l).
The following compounds in Table 38 are prepared essentially as described in the preparation of racemic N-((lSR,2RS,4RS)-l-(3-bromo-4-fluorophenyl)-4-hydroxy -2- (hydroxymethyl)cyclopentylcarbamothioyl)benzamide.
Table 38
Figure imgf000068_0002
Racemic N-(( 1 SR,2RS,4RS)- 1 -(3-Bromo-4-fluorophenyl)-2- (7V1Br)
6Of (hydroxymethyl)-4- 507, 509
isopropoxycyclopentylcarbamothioyljbenzamide (M-I)
48 Isolated as a mixture of diastereomers.
Preparation 61
Racemic N-((4aRS,6RS,7aSR)-7a-(3-Bromo-4-fluorophenyl)-6-hydroxy-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Figure imgf000069_0001
A solution of racemic N-((lSR,2RS,4RS)-l-(3-bromo-4-fluorophenyl)-4-hydroxy- 2-(hydroxymethyl)cyclopentylcarbamothioyl)benzamide (1.21 g, 2.02 mmol) and triphenylphosphine (0.690 mg, 2.63 mmol) in anhydrous THF (18 mL) is added to a separate solution of di-tert-butyl azodicarboxylate (0.606 g, 2.63 mmol) in THF (36 mL) at room temperature. The reaction mixture is stirred at room temperature for 1 hr and concentrated under reduced pressure to give a residue that is purified by silica gel chromatography eluting with a linear gradient of 0% to 40% ethyl acetate in
dichloromethane over 15 minutes to give the title compound as racemic mixture (0.557 g, 61%). ES/MS m/e (79Br/81Br) 449, 451 (M+l).
The following compounds in Table 39 are prepared essentially as described in the preparation of racemic N-((4aRS,6RS,7aSR)-7a-(3-bromo-4-fluorophenyl)-6-hydroxy- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide.
Table 39
Figure imgf000069_0002
Figure imgf000070_0002
Preparation 62
N-((4aR,6R,7aS)-7a-(3-Bromo-4-fluorophenyl)-6-hydroxy-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Figure imgf000070_0001
Racemic N-((4aRS,6RS,7aSR)-7a-(3-bromo-4-fluorophenyl)-6-hydroxy- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.492 g, 1.09 mmol) is purified by chiral HPLC: Column: Chiralcel OJ-H 3 x 25 cm; eluent: 75 : 25 (methanol : acetonitrile); flow: 40 mL/min at UV 225 nm. The second eluting isomer is isolated to provide the enantiomerically enriched title compound (0.171 g, 35%). ES/MS m/e (79Br/81Br) 449, 451 (M+l).
The following compounds in Table 40 are prepared essentially as described in the preparation ofN-((4aR,6R,7aS)-7a-(3-bromo-4-fluorophenyl)-6-hydroxy-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Table 40
Figure imgf000070_0003
Preparation 63 N-((4aR,6R,7aS)-7a-(4-Fluoro-3-(pyrimidin-5-yl)phenyl)-6-hydroxy-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-2-yl)benzamide
Figure imgf000071_0001
A solution ofN-((4aR,6R,7aS)-7a-(3-bromo-4-fluorophenyl)-6-hydroxy- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.588 g, 1.31 mmol) in a mixture of 1,2-dimethoxyethane (8 mL), ethanol (4 mL) and water (4 mL) is purged with nitrogen and is heated to 97 0C. Pyrimidine-5-boronic acid (0.810 g, 6.54 mmol), cesium carbonate (2.56 g, 7.84 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.184g, 0.261 mmol) is added in a single portion and the reaction is heated at 97 0C for 30 minutes. The reaction is cooled, diluted with water and is extracted twice with ethyl acetate. The organic layer is dried over sodium sulfate and the crude product is purified by silica gel chromatography with a linear gradient of 0% to 40% ethyl acetate in dichloromethane over 20 minutes to give the title compound (0.464 g, 79%). ES/MS m/e: 449 (M+ 1).
The following compounds in Table 41 are prepared essentially as described in the preparation ofN-((4aR,6R,7aS)-7a-(4-fluoro-3-(pyrimidin-5-yl)phenyl)-6-hydroxy- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide.
Table 41
Figure imgf000071_0002
Figure imgf000072_0002
49 2 Ν sodium carbonate solution is utilized instead of cesium carbonate.
Example 1
N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-4- fluorophenyl)-5-fluoropicolinamide hydrochloride
Figure imgf000072_0001
A solution of 4M hydrogen chloride in dioxane (834.8 μL; 3.3 mmol) is added to tert-butyl 7a-(5-(5-fluoropicolinamido)-2-fluorophenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-d][l,3]thiazin-2-ylcarbamate (91 mg; 167.0 μmol) and stirred at ambient temperature. After 2 days, the reaction mixture is concentrated in vacuo. The residue is dissolved in minimal dichloromethane and methanol. Ether and hexane are added. The product is precipitated as the salt which is separated from the mother liquor by centrifugation and placed under vacuum to remove any solvent present to give the title compound (58 mg; 125μmol). LC-ES/MS m/e 391 (M+l); TR = 1.675.
Example Ia
To a suspension of N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide (17.3 g, 42.10 mmol) in a mixture of ethanol (631.45 mL) and dichloromethane (420.96 mL) is added a solution of 4 M hydrogen chloride in 1,4-dioxane (46.31 mL, 185.22 mmol). The mixture is stirred at 22 0C for 1 h, concentrated and the residue is triturated with EtOH (200 mL). The solid is filtered off and washed with EtOH. The solid is triturated with water and the suspension is concentrated under reduced pressure. The residue is dried in a vacuum oven (18 h, 40 0C) to give the title compound as a white solid (17.1 g, 94%). ES/MS m/e: 391 (M+l).
Example Ib
N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-4- fluorophenyl)-5-fluoropicolinamide
To a suspension of N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide hydrochloride (20 g, 47 mmol) in water (280 mL) at room temperature is added an aqueous solution of 2Ν sodium hydroxide (1.2 eq, 27 mL). The mixture is stirred for 30 minutes. The suspension is filtered and the solid is washed with water (3 x 10OmL). The solid is dried under vacuum at 45 0C to give the title compound as a white solid. The resulting solid is purified via the following two methods:
Method A: The solid (16 g) is suspended in 240 mL of water and an aqueous solution of 2N sodium hydroxide is added (1.5eq, 3 ImL). The mixture is placed in an ultrasound bath for 15 min at 22 0C and stirred at 22 0C for 3 h. The white solid is filtered, washed with water (3 x 100 mL), and dried in a vacuum oven at 45 0C overnight to yield the title compound (14 g). ES/MS m/e 391(M+1). Method B : The solid (3 g) is suspended in methanol (40 mL) and heated between 62 to 64 0C for 15 h with seeding with seeds of the free base of N-(3-((4aS,7aS)-2-Amino- 4a,5,7,7a-tetrahydro-4H-fiiro[3,4-d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5- fluoropicolinamide. The mixture is cooled to room temperature and the slurry is filtered. The solid is washed with methanol and dried in a vacuum oven at 50 0C for 4 h to yield the title compound (2.3 g). ES/MS m/e 391 (M+l).
Example 2
N-(3-((4aS,7aS)-2-Amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-5- fluorophenyl)-5-fluoropicolinamide dihydrochloride
Figure imgf000074_0001
Pyridine (0.44mL, 5.46 mmol) is added to a mixture of N-(3-((4aS,7aS)-2- benzamido-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-5-fluorophenyl)-5- fluoropicolinamide (0.27g, 0.546 mmol) and 0-methylhydroxylamine hydrochloride (0.456 g, 5.46 mmol) in ethanol (15 mL). The resulting mixture is stirred at 50 0C for 6 h. The mixture is cooled to room temperature and stirring is continued for 3 days. The mixture is diluted with dichloromethane and aqueous 0.1 M ΝaOΗ and is extracted five times with dichloromethane. The combined organic phase is diluted with MeOH to make a homogenous solution, dried over sodium sulfate, filtered, and the solvent is removed under reduced pressure to give a residue that is purified on silica gel with 5% methanol in dichloromethane to give the title compound as the freebase (0.109 g, 51%). Hydrogen chloride is bubbled through the solution of N-(3-((4aS,7aS)-2-amino-4a,5,7,7a- tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-5-fluorophenyl)-5-fluoropicolinamide (0.109 g, 0.279 mmol) in methanol for approximately 5 min. The solution is then concentrated under reduced pressure and dried on high vacuum to yield the title compound (0.128 g, 51%). ES/MS m/e: 391 (M+l) The following compounds in Table 42 are prepared essentially as described in the preparation of N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin- 7a-yl)-5-fluorophenyl)-5-fluoropicolinamide dihydrochloride.
Table 42
Figure imgf000075_0002
Example 5
N-(3-((8aS)-2-Amino-4,4a,5,7,8,8a-hexahydropyrano[4,3-d][l,3]thiazin-8a-yl)phenyl)-5- chloropicolinamide dihydrochloride
Figure imgf000075_0001
To a solution of tert-butyl (8aS)-8a-(3-(5-chloropicolinamido)phenyl)-
4,4a,5,7,8,8a-hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (0.172 g, 0.342 mmol) in CH2CI2 (8 mL) is added TFA (4 mL) and the reaction is stirred at room temperature for 1 hour. The solvent is removed under reduced pressure. The residue is purified on a 10 g SCX column using 4 : 1 CH2Cl2 : MeOH followed by 2 : 1 CH2Cl2 : 7 Ν NH3 in MeOH to afford the title compound as a freebase (0.127 g, 92%). The freebase (0.124 g, 0.308 mmol) is dissolved in CH2Cl2 and treated with 1 M HCl in Et2O (0.65 mL, 0.605 mmol) and the solvent is removed under reduced pressure to afford the title compound (0.127 g, 78%). ES/MS m/e (35C1/37C1) 403, 405 (M+ 1).
The following compounds in Table 43 are prepared essentially as described in the preparation ofN-(3-((8aS)-2-amino-4,4a,5,7,8,8a-hexahydropyrano[4,3-d][l,3]thiazin-8a- yl)phenyl)-5 -chloropicolinamide dihydrochloride.
Table 43
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
50 4 N HCl in 1,4-dioxane is utilized for deprotection instead of TFA to afford the HCl salt directly.
51 HCl gas in dichloromethane/diethyl ether is utilized for deprotection instead of TFA to afford the HCl salt directly.
Example 23
(8aS)-8a-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4,4a,5,7,8,8a-hexahydropyrano[4,3- d][l,3]thiazin-2-amine dihydrochloride
Figure imgf000079_0001
To a solution of tert-butyl 8a-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-
4,4a,5,7,8,8a-hexahydropyrano[4,3-d][l,3]thiazin-2-ylcarbamate (0.258 g, 0.558 mmol) in CH2CI2 (8 mL) is added TFA (4 mL) and the reaction is stirred at room temperature for 1 hour. The solvent is removed under reduced pressure to afford a residue that is diluted with water and 1 N NaOH to adjust the pH to 12. The aqueous layer is extracted three times with EtOAc. The organic layer is dried over Na2SO4 and the crude product is purified by silica gel chromatography eluting with a linear gradient of 1% to 10% 7 N NH3MeOH in CH2Cl2 to afford the title compound as the freebase (0.165 g, 68%). The freebase (0.162 g, 0.448 mmol) is dissolved in CH2Cl2 and treated with of 1 M HCl in Et2O (0.94 mL, 0.940 mmol) and the solvent is removed under reduced pressure to afford the title compound (0.208 g, 86%). ES/MS m/e: 363 (M+l).
Example 24
(4aR,7aS)-7a-(3-(Pyrimidin-5-yl)phenyl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-amine dihydrochloride
Figure imgf000080_0001
A mixture of tert-butyl (4aR,7aS)-7a-(3-bromophenyl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-ylcarbamate (0.860 g, 2.09 mmol), pyrimidine-5- boronic acid (0.423 g , 3.34 mmol), (l,r-bis(diphenylphosphino)ferrocene)palladium(II) chloride (0.171 g, 0.209 mmol) in 1,2-dimethoxyethane (10 mL) is heated to 100 0C under nitrogen atmosphere. Aqueous 2 M sodium carbonate (3.14 mL, 6.27 mmol) is added to the reaction mixture by syringe. The resulting mixture is stirred at 110 0C for 20 minutes. The reaction is cooled and extracted three times with dichloromethane and the combined extracts are dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue is purified by silica gel chromatography, eluting with a linear gradient of methanol in dichloromethane 0 to 20% over 30 minutes to give the title compound as a freebase (0.482 g, 74%). ES/MS m/e: 311 (M+l).
To the solution of (4aR,7aS)-7a-(3-(pyrimidin-5-yl)phenyl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-amine (0.482 g, 1.55 mmol) in methanol (2 mL) is added 4 N HCl in 1,4-dioxane (2 mL) at room temperature. The resulting mixture is stirred at room temperature for 1 hour and is concentrated under reduced pressure to give the title compound (0.595 g, 100%). ES/MS m/e: 311 (M+l).
The following compound in Table 44 is prepared essentially as described in the preparation of (4aR,7aS)-7a-(3-(pyrimidin-5-yl)phenyl)-4,4a,5, 6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-amine dihydrochloride.
Table 44
Figure imgf000080_0002
Figure imgf000081_0002
Example 26
(7aS)-7a-(4-Fluoro-3-(pyrimidin-5-yl)phenyl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d][l,3]thiazin-2-amine dihydrochloride
Figure imgf000081_0001
To a mixture of 5-((4aR,7aS)-2-(tert-butoxycarbonylamino)-4,4a,5, 6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-7a-yl)-2-fluorophenyl trifluoromethanesulfonate (0.630 g, 1.26 mmol), pyrimidin-5-ylboronic acid (0.189 g, 1.53 mmol),
tricyclohexylphosphine (0.035 g, 0.125 mmol) and
tris(dibenzylideneacetone)dipalladium (0) (0.057 g, 0.0622 mmol) in 1,4-dioxane (6 mL) is added 1.27 M aqueous potassium phosphate, tribasic, N-hydrate (1.76 mL, 2.24 mmol). The mixture is heated to 73 0C and stirred overnight. The reaction is cooled and diluted with water and EtOAc. The organic layer is dried over Na2SO4 and evaporated to dryness and the crude product is purified by silica gel chromatography eluting with a linear gradient of 1% to 10% 7 N NH3MeOH in CH2Cl2 to afford the title compound as the freebase (0.191 g, 46%). The freebase (0.191 g, 0.582 mmol) is dissolved in CH2Cl2 and treated with of 1 M HCl in Et2O (1.16 mL, 1.16 mmol) and the solvent is removed under reduced pressure to afford the title compound (0.24 g, 47.5%). ES/MS m/e: 329 (M+l).
Example 27
(4aR,6R,7aS)-2-Amino-7a-(3'-methoxybiphenyl-3-yl)-4,4a,5,6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-6-ol hydrochloride
Figure imgf000082_0001
A mixture of N-((4aR,6R,7aS)-6-hydroxy-7a-(3 '-methoxybiphenyl-3 -yl)- 4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin-2-yl)benzamide (0.061g, 0.133 mmol), o-methylhydroxylamine hydrochloride (0.111 g, 1.3 mmol) and pyridine (0.105 g, 1.30 mmol) in ethanol (5 mL) is heated to 50 0C for 15 h. The mixture is concentrated under reduced pressure. The crude product is purified by silica gel chromatography eluting with 0.5% to 10% ΝH3 (7 N solution in methanol) in dichloromethane over 30 minutes to afford the title compound as a freebase (0.041 g, 87%). ES/MS m/e: 355 (M+l). A l N solution of HCl in Et2O (0.139 mL, 0.139 mmol) is added to a solution of (4aR,6R,7aS)- 2-amino-7a-(3'-methoxybiphenyl-3-yl)-4,4a,5,6,7,7a-hexahydrocyclopenta[d][l,3]thiazin- 6-0I (0.04 Ig, 0.116 mmol) in minimal dichloromethane and methanol. The solvent is removed under reduced pressure to give the title compound (0.045 g, 86%). ES/MS m/e: 355 (M+l).
The following compounds in Table 45 are prepared essentially as described in the preparation (4aR,6R,7aS)-2-amino-7a-(3'-methoxybiphenyl-3-yl)-4,4a,5, 6,7,7a- hexahydrocyclopenta[d] [ 1 ,3 ]thiazin-6-ol hydrochloride.
Table 45
Figure imgf000082_0002
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Example 42
(4aS,7aS)-7a-(2,4-Difluoro-5-(5-fluoropyridin-3-yl)phenyl)-4a,5,7,7a-tetrahydro-4H- furo [3 ,4-d] [ 1 ,3 ]thiazin-2-amine dihydrochloride
Figure imgf000085_0002
5 N Aqueous hydrochloric acid (8.70 mL) is added to N-((4aS,7aS)-7a-(2,4- difluoro-5-(5-fluoropyridin-3-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin- 2-yl)benzamide (0.252 g, 0.435 mmol) in methanol (4 mL) and the mixture is heated to 90 0C. After 18 hours, the heat is removed and the pΗ of the reaction mixture is adjusted to basic with 5 Ν aqueous sodium hydroxide. The mixture is extracted three times with 10% isopropyl alcohol in dichloromethane. The organic layer is concentrated under reduced pressure and the resulting residue is purified by radial chromatography eluting with 3% 2 M ammonia in methanol : dichloromethane to give the title compound as the freebase. The free base is dissolved in minimal dichloromethane and 1 M hydrogen chloride in ether is added in excess. Ηexane (1 mL) is added and the solvent is removed under reduced pressure to give the title compound (0.129 g, 67%). ES/MS m/e: 366 (M+l). The following compounds in Table 46 are prepared essentially by the method of (4aS,7aS)-7a-(2,4-difluoro-5-(5-fluoropyridin-3-yl)phenyl)-4a,5,7,7a-tetrahydro-4H- furo[3,4-d][l,3]thiazin-2-amine dihydrochloride.
Figure imgf000086_0002
Example 45
(4aS,7aS)-7a-(4-Fluoro-3-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-2-amine dihydrochloride
Figure imgf000086_0001
A solution of 1 M hydrogen chloride in diethyl ether is added in excess to
(4aS,7aS)-7a-(4-fluoro-3-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-2-amine (22 mg, 66.59 μmol) in minimal dichloromethane. The solvent is removed under reduced pressure to give the title compound (27mg, 100%). LC-ES/MS m/e: 331 (M+l).
The following compounds in Table 47 are prepared essentially by the method of
(4aS,7aS)-7a-(4-fluoro-3-(pyrimidin-5-yl)phenyl)-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-2-amine dihydrochloride.
Figure imgf000087_0001
In vitro Assay Procedures:
For in vitro enzymatic and cellular assays, test compounds are prepared in DMSO to make up a 10 mM stock solution. The stock solution is serially diluted in DMSO to obtain a ten-point dilution curve with final compound concentrations ranging from 10 mM to 1 nM in a 96-well round-bottom plate before conducting the in vitro enzymatic and whole cell assays.
In vitro protease inhibition assays: BACEl FRET Assay
Serial dilutions of test compounds are prepared as described above. Compounds are further diluted 2OX in KH2PO4 buffer. Ten μL of each dilution is added to each well on row A to H of a corresponding low protein binding black plate containing the reaction mixture (25 μL of 50 mM KH2PO4, pH 4.6, 1 mM TRITON® X-IOO, 1 mg/mL Bovine Serum Albumin, and 15 μM of FRET substrate) (See Yang, et. ah, J. Neurochemistry, 91(6) 1249-59 (2004)). The content is mixed well on a plate shaker for 10 minutes. Fifteen μL of two hundred pM human BACEl(l-460):Fc (See Vasser, et ah, Science, 286, 735-741 (1999)) in the KH2PO4 buffer is added to the plate containing substrate and test compounds to initiate the reaction. The RFU of the mixture at time 0 is recorded at excitation wavelength 355 nm and emission wavelength 460 nm, after brief mixing on a plate shaker. The reaction plate is covered with aluminum foil and kept in a dark humidified oven at room temperature for 16 to 24 h. The RFU at the end of incubation is recorded with the same excitation and emission settings used at time 0. The difference of the RFU at time 0 and the end of incubation is representative of the activity of BACEl under the compound treatment. RFU differences are plotted versus inhibitor
concentration and a curve is fitted with a four-parameter logistic equation to obtain the EC50 and IC50 values. (See Sinha, et ah, Nature, 402, 537-540 (2000)).
The compounds exemplified herein were tested essentially as described above and exhibited an IC50 value for BACEl of lower than 1 μM. The following exemplified compounds were tested essentially as described above and exhibited the following activity for BACEl :
Table 48
Figure imgf000088_0001
These data demonstrate that the compounds of Table 48 inhibit purified recombinant BACEl enzyme activity in vitro.
Expression of human BACEl
Human BACEl (accession number: AF 190725) is cloned from total brain cDNA by room temperature-PCR. The nucleotide sequences corresponding to amino acid sequences #1 to 460 are inserted into the cDNA encoding human IgGi (Fc) polypeptide (Vassar et al. 1999). This fusion protein of BACEl (1-460) and human Fc, named /zwBACEl:Fc, is constructed into the pJB02 vector. Human BACEl(l-460):Fc
(/zwBACEl:Fc) is transiently expressed in HEK293 cells. 250 μg cDNA of each construct is mixed with Fugene 6 and added to 1 liter HEK293 cells. Four days after the transfection, conditioned media are harvested for purification.
Purification of /zwBACEl :Fc.
/zwBACEl :Fc is purified by Protein A chromatography. The enzyme is stored at - 80 0C in small aliquots.
Whole cell assays for measuring the Inhibition of Beta-Secretase Activity
HEK293Swe Whole Cell Assay
The routine whole cell assay for the measurement of inhibition of beta-secretase activity utilizes the human embryonic kidney cell line HEK293p (ATCC Accession No. CRL-1573) stably expressing a human APP751 cDNA containing the naturally occurring double mutation Lys651Met652 to Asn651Leu652, commonly called the Swedish mutation (noted HEK293/APP751sw) and shown to overproduce Abeta (Citron, et ah, Nature, 360, 672-674 (1992)). In vitro Abeta reduction assays have been described in the literature (See Dovey, et ah, Journal of Neurochemistry, 76, 173-181 (2001); Seubert, et ah, Nature, 361, 260 (1993); and Johnson- Wood, et ah, Proc. Natl. Acad. ScL USA, 94, 1550-1555 (1997)).
Cells (HEK293/APP751sw at 3.5xlO4 cells/well, containing 200 μL culture media, DMEM containing 10% FBS) are incubated at 37 0C for 4 to 24 h in the presence/absence of inhibitors (diluted in DMSO) at the desired concentration. At the end of the incubation, conditioned media are analyzed for evidence of beta-secretase activity, for example, by analysis of Abeta peptides. Total Abeta peptides (Abeta 1-x) are measured by a sandwich ELISA, using monoclonal 266 as a capture antibody and biotinylated 3D6 as reporting antibody. Alternatively, Abeta 1-40 and Abeta 1-42 peptides are measured by a sandwich ELISA, using monoclonal 2G3 as a capture antibody for Abeta 1-40, and monoclonal 2 IF 12 as a capture antibody for Abeta 1-42. Both Abeta 1-40 and Abeta 1-42 ELISAs use biotinylated 3D6 as the reporting antibody. The concentration of Abeta released in the conditioned media following the compound treatment corresponds to the activity of BACEl under such conditions. The 10-point inhibition curve is plotted and fitted with the four-parameter logistic equation to obtain the EC50 and IC50 values for the Abeta-lowering effect. The following exemplified compounds were tested essentially as described above and exhibited the following activity for Abeta lowering effect: Table 49
Figure imgf000090_0001
These data demonstrate that the compounds of Table 49 inhibit native endogenous human BACEl in cells in vitro.
PDAPP Primary Neuronal Assay
A confirmatory whole cell assay is also run in primary neuronal cultures generated from PDAPP transgenic embryonic mice. Primary cortical neurons are prepared from Embryonic Day 16 PDAPP embryos and cultured in 96 well plates (15 x 104 cells/well in DMEM/F12 (1: 1) plus 10% FBS). After 4-6 days in vitro, culture media is replaced with serum free DMEM/F12 (1: 1) containing B27 supplement and neurons are incubated at 37 0C for 24 h in the presence/absence of inhibitors (diluted in DMSO) at the desired concentration. At the end of the incubation, conditioned media are analyzed for evidence of beta-secretase activity, for example, by analysis of Abeta peptides. Total Abeta peptides (Abeta 1-x) are measured by a sandwich ELISA, using monoclonal 266 as a capture antibody and biotinylated 3D6 as reporting antibody. Alternatively, Abeta 1-40 and Abeta 1-42 peptides are measured by a sandwich ELISA, using monoclonal 2G3 as a capture antibody for Abeta 1-40, and monoclonal 2 IF 12 as a capture antibody for Abeta 1-42. Both Abeta 1-40 and Abeta 1-42 ELISAs use biotinylated 3D6 as the reporting antibody. The concentration of Abeta released in the conditioned media following the compound treatment corresponds to the activity of BACEl under such conditions. The 10-point inhibition curve is plotted and fitted with the four-parameter logistic equation to obtain the EC50 and IC50 values for the Abeta-lowering effect. The following exemplified compounds were tested essentially as described above and exhibited the following activity for Abeta lowering effect:
Table 50
Figure imgf000091_0001
These data demonstrate that the compounds of Table 50 inhibit native, endogenous murine BACEl in cells in vitro.
In vivo Inhibition of Beta-Secretase Several animal models, including mouse, guinea pig, dog, and monkey, may be used to screen for inhibition of beta- secretase activity in vivo following compound treatment. Animals used in this invention can be wild type, transgenic, or gene knockout animals. For example, the PDAPP mouse model, prepared as described in Games et al., Nature 373, 523-527 (1995), and other non-transgenic or gene knockout animals are useful to analyze in vivo inhibition of Abeta and sAPPbeta production in the presence of inhibitory compounds. Generally, 2 to 12 month old PDAPP mice, gene knockout mice or non-transgenic animals are administered compound formulated in vehicles, such as corn oil, cyclodextran, phosphate buffers, PHARMASOLVE®, or other suitable vehicles. One to twenty- four hours following the administration of compound, animals are sacrificed, and brains as well as cerebrospinal fluid and plasma are removed for analysis of Abetas, C99, and sAPP fragments. (See Dovey, et al, Journal ofNeurochemistry, 76, 173-181 (2001); and Johnson- Wood, et al, Proc. Natl Acad. Sci. USA, 94, 1550-1555 (1997)).
For standard in vivo pharmacology studies, animals are dosed with various concentrations of compound and compared to a vehicle-treated control group dosed at the same time. For some time course studies, brain tissue, plasma, or cerebrospinal fluid is obtained from selected animals, beginning at time 0 to establish a baseline. Compound is administered to other groups and sacrificed at various times after dosing. Brain tissue, plasma, or cerebrospinal fluid is obtained from selected animals and analyzed for the presence of APP cleavage products, including Abeta peptides, sAPPbeta, and other APP fragments, for example, by specific sandwich ELISA assays. At the end of the test period, animals are sacrificed and brain tissues, plasma, or cerebrospinal fluid are analyzed for the presence of Abeta peptides, C99, and sAPPbeta, as appropriate. Brain tissues of APP transgenic animals are also analyzed for the amount of beta-amyloid plaques following compound treatment.
Animals (PDAPP or other APP transgenic or non-trans genie mice) administered an inhibitory compound may demonstrate the reduction of Abeta or sAPPbeta in brain tissues, plasma or cerebrospinal fluids and decrease of beta amyloid plaques in brain tissue, as compared with vehicle-treated controls or time zero controls. For example, 3 hours after administration of 10 mg/kg subcutaneous dose of the compound of Example 1 to young female PDAPP mice, Abeta 1 -x peptide, C99 and sAPPb levels are reduced approximately 64%, 60%, and 44% in brain cortex, respectively, compared to vehicle- treated mice. Similarly, 3 hours after administration of a 10 mg/kg oral dose of the compound of Example 1 to young female PDAPP mice, Abeta 1-x peptide, C99 and sAPPb levels are reduced approximately 54%, 34% and 42% in brain cortex, respectively, compared to vehicle-treated mice. Consistent with changes in brain Abeta, C99 and sAPPb, 3 hours after oral administration of a 10 mg/kg dose of the compound of Example 1, CSF Abeta 1-x and 1-42 levels are reduced by approximately 62% and 62%, respectively. Consistent with a mechanism of BACE inhibition in vivo, CSF sAPPbeta levels are reduced 22%, while CSF sAPPalpha levels are unchanged 3 hours after oral administration of a 10 mg/kg dose of the compound of Example 1. The compounds of the present invention are preferably formulated as
pharmaceutical compositions administered by a variety of routes. Most preferably, such compounds are for oral administration. Such pharmaceutical compositions and processes for preparing same are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy (A. Gennaro, et. ah, eds., 19th ed., Mack Publishing Co., 1995).
The compounds of Formula I are generally effective over a wide dosage range.
For example, dosages per day normally fall within the range of about 0.01 to about 30 mg/kg of body weight. In some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, and therefore the above dosage range is not intended to limit the scope of the invention in any way. It will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.

Claims

We Claim:
1. A compound of Formula I:
Figure imgf000094_0001
wherein:
X is -CH2- Or -O-;
n is 0 or 1;
m is 0, 1, or 2;
p is 0 or 1 ; p must be 0 when X is -O-;
R1 is -NHCOR4, pyrimidinyl, pyridinyl optionally substituted with halo or phenyl optionally monosubstituted with -C1-C3 alkoxy;
R2 is halo;
R3 is -C1-C3 alkoxy, hydroxy, Or -O-CH2-O-CH3; and
R4 is phenyl, pyridinyl optionally substituted with halo, pyrimidinyl optionally substituted with halo, pyrizinyl, or thiazolyl;
or a pharmaceutically acceptable salt thereof.
2. A compound of Claim 1 wherein X is -CH2- or -O-; n is 0 or 1; m is 0 or 1; p is 0 or 1 ; p must be 0 when X is -O-; R1 is -NHCOR4 or pyrimidinyl; R2 is fluoro; R3 is -C1-C3 alkoxy or hydroxy; R4 is pyridinyl optionally substituted with halo, or pyrimidinyl optionally substituted with halo; or a
pharmaceutically acceptable salt thereof.
3. A compound of any of Claims 1 to 2 wherein X is -CH2- or -O-; n is 0 or 1; m is 0 or 1; p is 0; R1 is -NHCOR4; R2 is fluoro; R4 is pyridinyl optionally substituted with halo; or a pharmaceutically acceptable salt thereof.
4. A compound of any of Claims 1 to 3 wherein X is -O-; n is 0; m is 1; p is 0; R1 is -NHCOR4; R2 is halo; R4 is pyridinyl substituted with halo, or a pharmaceutically acceptable salt thereof.
5. A compound of Claim 4 wherein R2 is fluoro, or a pharmaceutically
acceptable salt thereof.
6. A compound of any of Claims 1 to 5 wherein the compound possesses a cis configuration at the chiral centers at the junction of the fused aminothiazine ring, or a pharmaceutically acceptable salt thereof.
7. A compound N-(3-((4a,7a)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4- d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide:
Figure imgf000095_0001
or a pharmaceutically acceptable salt thereof.
8. A compound of Claim 7 wherein the compound is N-(3-((4aS,7aS)-2-amino-
4a,5,7,7a-tetrahydro-4H-furo[3,4-d][l,3]thiazin-7a-yl)-4-fluorophenyl)-5- fluoropicolinamide:
Figure imgf000095_0002
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical formulation comprising a compound of any of Claims 1 to 8, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
10. A pharmaceutical formulation of Claim 9 further comprising one or more other therapeutic agents.
11. A method of treating Alzheimer's disease by administering an effective
amount of a compound of any of Claims 1 to 8, or a pharmaceutically acceptable salt thereof.
12. A compound of any of Claims 1 to 8, or a pharmaceutically acceptable salt thereof, or a pharmaceutical formulation of any of Claims 9 to 10, for use in therapy.
13. The use of a compound of any of Claims 1 to 8, or a pharmaceutically
acceptable salt thereof, or a pharmaceutical formulation of any of Claims 9 to 10, for the treatment of Alzheimer's disease.
14. The use of a compound of Claims 1 to 8, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of Alzheimer's disease.
PCT/US2010/041034 2009-07-09 2010-07-06 Bace inhibitors WO2011005738A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EA201270149A EA019892B1 (en) 2009-07-09 2010-07-06 Bace inhibitors
CA2764429A CA2764429C (en) 2009-07-09 2010-07-06 Condensed aminodihydrothiazine derivatives as bace inhibitors
JP2012519660A JP5666578B2 (en) 2009-07-09 2010-07-06 BACE inhibitor
MX2012000510A MX2012000510A (en) 2009-07-09 2010-07-06 Bace inhibitors.
CN201080030698.1A CN102471296B (en) 2009-07-09 2010-07-06 Bace inhibitors
KR1020127000457A KR101362557B1 (en) 2009-07-09 2010-07-06 Bace inhibitors
MA34517A MA33492B1 (en) 2009-07-09 2010-07-06 BACE INHIBITORS
EP10731890.9A EP2451793B1 (en) 2009-07-09 2010-07-06 Bace inhibitors
NZ596579A NZ596579A (en) 2009-07-09 2010-07-06 Bace inhibitors
BR112012000525A BR112012000525A2 (en) 2009-07-09 2010-07-06 bace inhibitors
AU2010270691A AU2010270691B8 (en) 2009-07-09 2010-07-06 BACE inhibitors
SG2012001749A SG177594A1 (en) 2009-07-09 2010-07-06 Bace inhibitors
IL216742A IL216742A0 (en) 2009-07-09 2011-12-01 Bace inhibitors
ZA2011/09385A ZA201109385B (en) 2009-07-09 2011-12-20 Bace inhibitors
TNP2011000673A TN2011000673A1 (en) 2009-07-09 2011-12-28 Bace inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22424109P 2009-07-09 2009-07-09
US61/224,241 2009-07-09

Publications (1)

Publication Number Publication Date
WO2011005738A1 true WO2011005738A1 (en) 2011-01-13

Family

ID=42985394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/041034 WO2011005738A1 (en) 2009-07-09 2010-07-06 Bace inhibitors

Country Status (26)

Country Link
US (2) US8278441B2 (en)
EP (1) EP2451793B1 (en)
JP (1) JP5666578B2 (en)
KR (1) KR101362557B1 (en)
CN (1) CN102471296B (en)
AR (1) AR077277A1 (en)
AU (1) AU2010270691B8 (en)
BR (1) BR112012000525A2 (en)
CA (1) CA2764429C (en)
CL (1) CL2012000033A1 (en)
CO (1) CO6480979A2 (en)
CR (1) CR20120011A (en)
DO (1) DOP2012000004A (en)
EA (1) EA019892B1 (en)
EC (1) ECSP12011581A (en)
HN (1) HN2012000012A (en)
IL (1) IL216742A0 (en)
MA (1) MA33492B1 (en)
MX (1) MX2012000510A (en)
NZ (1) NZ596579A (en)
PE (1) PE20120632A1 (en)
SG (1) SG177594A1 (en)
TN (1) TN2011000673A1 (en)
TW (1) TWI405765B (en)
WO (1) WO2011005738A1 (en)
ZA (1) ZA201109385B (en)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168630B2 (en) 2007-04-24 2012-05-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
WO2012093148A1 (en) * 2011-01-06 2012-07-12 Eisai R&D Management Co., Ltd Fused aminodihydrothiazine derivatives
WO2012100179A1 (en) * 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
WO2012098213A1 (en) 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives useful as bace inhibitors
WO2012098461A1 (en) 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2013004676A1 (en) * 2011-07-06 2013-01-10 F. Hoffmann-La Roche Ag Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
JPWO2011071109A1 (en) * 2009-12-11 2013-04-22 塩野義製薬株式会社 Fused heterocyclic compounds having an amino group
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2014013076A1 (en) 2012-07-20 2014-01-23 Eisai R&D Management Co., Ltd. Hexahydropyrrolothiazine compounds
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
WO2014098831A1 (en) 2012-12-19 2014-06-26 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
US9079914B2 (en) 2009-07-22 2015-07-14 Eisai R&D Management Co., Ltd. Fused aminodihydro-oxazine derivatives
US9096615B2 (en) 2013-07-30 2015-08-04 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
US9139594B2 (en) 2009-07-22 2015-09-22 Eisai R&D Management Co., Ltd. Fused aminodihydropyrimidone derivatives
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
JP2015535247A (en) * 2012-10-26 2015-12-10 イーライ リリー アンド カンパニー BACE inhibitor
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9227942B2 (en) 2012-04-27 2016-01-05 Eisai R&D Management Co., Ltd. Method for producing 5-(difluoromethyl)pyrazine-2-carboxylic acid and production intermediate thereof
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9296734B2 (en) 2013-03-01 2016-03-29 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9309263B2 (en) 2013-01-29 2016-04-12 Amgen Inc. Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
WO2016149057A1 (en) * 2015-03-19 2016-09-22 Eli Lilly And Company Selective bace1 inhibitors
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US9611261B2 (en) 2013-03-08 2017-04-04 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2018112081A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
WO2018112083A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018112086A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018112084A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
WO2018112094A1 (en) 2016-12-15 2018-06-21 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8158620B2 (en) * 2008-01-18 2012-04-17 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
CN102105475B (en) * 2008-07-28 2014-04-09 卫材R&D管理有限公司 Spiroaminodihydrothiazine derivatives
ES2539859T3 (en) * 2008-09-30 2015-07-06 Eisai R&D Management Co., Ltd. New condensed aminodihydrotiazine derivative
CA2799640C (en) 2010-06-09 2018-10-16 Janssen Pharmaceutica Nv 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
ES2648143T3 (en) 2010-12-22 2017-12-28 Janssen Pharmaceutica Nv 5,6-Dihydro-imidazo [1,2-a] pyrazin-8-ylamine derivatives useful as beta-secretase inhibitors (BACE)
JP5853035B2 (en) 2011-03-09 2016-02-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 3,4-Dihydro-pyrrolo [1,2-a] pyrazin-1-ylamine derivatives useful as inhibitors of β-secretase (BACE)
JP6043355B2 (en) 2011-08-31 2016-12-14 ファイザー・インク Hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compound
JO3143B1 (en) 2012-04-03 2017-09-20 Lilly Co Eli Tetrahydropyrrolothiazine compounds
EP2852597B1 (en) 2012-05-04 2016-06-08 Pfizer Inc Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2.
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
EP2935282A1 (en) 2012-12-19 2015-10-28 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
TWI593692B (en) 2013-03-12 2017-08-01 美國禮來大藥廠 Tetrahydropyrrolothiazine compounds
BR112015030597A2 (en) 2013-06-12 2017-07-25 Janssen Pharmaceutica Nv 4-amino-6-phenyl-6,7-dihydro [1,2,3] triazolo [1,5-a] pyrazine derivatives as beta-secretase (bace) inhibitors
MX368326B (en) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace).
TWI639607B (en) * 2013-06-18 2018-11-01 美國禮來大藥廠 Bace inhibitors
CR20160455A (en) 2014-04-10 2016-12-16 Pfizer 2-AMINO-6-METHYL-4,4a, 5,6-TETRAHYDROPIRANE [3,4-d] [1,3] TIAZIN-8a (8H) -IL-1,3-TIAZOL-4-ILA
JO3458B1 (en) 2014-11-10 2020-07-05 H Lundbeck As 2-Amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
MA40941A (en) 2014-11-10 2017-09-19 H Lundbeck As 2-AMINO-5,5-DIFLUORO-6- (FLUOROMETHYL) -6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
CR20170187A (en) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment of Alzheimer's disease
ES2768823T3 (en) 2014-12-18 2020-06-23 Janssen Pharmaceutica Nv 2,3,4,5-Tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrole-5-amine derivatives useful as beta-secretase inhibitors
AR103680A1 (en) 2015-02-23 2017-05-24 Lilly Co Eli BACE1 SELECTIVE INHIBITORS
AR104241A1 (en) 2015-04-29 2017-07-05 Lilly Co Eli THIAZINE TETRAHYDROFIDE DERIVATIVES AS SELECTIVE BACE1 INHIBITORS
TW201717948A (en) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines
JP2018531889A (en) 2015-08-12 2018-11-01 ハー・ルンドベック・アクチエゼルスカベット 2-Amino-3-fluoro-3- (fluoromethyl) -6-methyl-6-phenyl-3,4,5,6-tetrahydropyridine as a BACE1 inhibitor
WO2017025565A1 (en) * 2015-08-12 2017-02-16 H. Lundbeck A/S 2-amino-7a-phenyl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines as bace1 inhibitors
JP2018534251A (en) 2015-09-24 2018-11-22 ファイザー・インク N- [2- (3-Amino-2,5-dimethyl-1,1-dioxide-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl) -1 useful as a BACE inhibitor , 3-Thiazol-4-yl] amide
JP2018531923A (en) * 2015-09-24 2018-11-01 ファイザー・インク N- [2- (2-Amino-6,6-disubstituted-4,4a, 5,6-tetrahydropyrano [3,4-d] [1,3] thiazin-8a (8H) -yl)- 1,3-thiazol-4-yl] amide
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
TWI675034B (en) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 Tetrahydrofurooxazine compounds and their use as selective bace1 inhibitors
WO2018083247A1 (en) 2016-11-04 2018-05-11 Janssen Pharmaceutica Nv 4,4a,5,7-tetrahydro-3h-furo[3,4-b]pyridinyl compounds
AU2018229722A1 (en) * 2017-03-07 2019-08-08 Janssen Pharmaceutica Nv Inhibitors of beta secretase
JP2020509068A (en) * 2017-03-07 2020-03-26 ヤンセン ファーマシューティカ エヌ．ベー． β-secretase inhibitor
CN110382506A (en) * 2017-03-07 2019-10-25 詹森药业有限公司 The inhibitor of beta-secretase
WO2018162444A1 (en) * 2017-03-07 2018-09-13 Janssen Pharmaceutica Nv Inhibitors of beta secretase
WO2018162445A1 (en) * 2017-03-07 2018-09-13 Janssen Pharmaceutica Nv Inhibitors of beta secretase
WO2018162443A1 (en) * 2017-03-07 2018-09-13 Janssen Pharmaceutica Nv Inhibitors of beta secretase
CN110590517A (en) * 2019-09-24 2019-12-20 武汉嘉诺康医药技术有限公司 Preparation method of 3, 4-dihydroxy-2' -chloroacetophenone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049532A1 (en) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
WO2008133274A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
US20090209755A1 (en) * 2008-01-18 2009-08-20 Yuichi Suzuki Fused aminodihydrothiazine derivatives
US20100093999A1 (en) * 2008-09-30 2010-04-15 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101061113A (en) * 2004-11-23 2007-10-24 默克公司 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
CN101360722A (en) * 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 Novel 2-aminopyrimidine derivatives and their use
ITTO20070665A1 (en) * 2007-09-24 2009-03-25 Rottapharm Spa AMIDINE, TIOUREIC AND GUANIDINE DERIVATIVES OF 2-AMMINOBENZOTIAZOLI AND AMMINOBENZOTIAZINE, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES.
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049532A1 (en) 2005-10-25 2007-05-03 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
WO2008133274A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
US20090209755A1 (en) * 2008-01-18 2009-08-20 Yuichi Suzuki Fused aminodihydrothiazine derivatives
US20100093999A1 (en) * 2008-09-30 2010-04-15 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ALDRICHIMICA ACTA, vol. 17, no. 1, 1984
CITRON ET AL., NATURE, vol. 360, 1992, pages 672 - 674
DOVEY ET AL., JOURNAL OF NEUROCHEMISTRY, vol. 76, 2001, pages 173 - 181
DURHAM; SHEPHERD, CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, vol. 9, no. 6, 2006, pages 776 - 791
GAMES ET AL., NATURE, vol. 373, 1995, pages 523 - 527
JOHNSON-WOOD ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 1550 - 1555
MORRIS ET AL., ARCH. NEUROL., vol. 58, 2001, pages 397 - 405
PARK; LEE, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 125, no. 52, 2003, pages 16416 - 16422
PETERSEN ET AL., ARCH. NEUROL., vol. 56, 1999, pages 303 - 308
S.M. BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, January 1977 (1977-01-01), XP002675560, DOI: doi:10.1002/jps.2600660104
SEUBERT ET AL., NATURE, vol. 361, 1993, pages 260
SINHA ET AL., NATURE, vol. 402, 2000, pages 537 - 540
VASSER ET AL., SCIENCE, vol. 286, 1999, pages 735 - 741
YANG, J NEUROCHEMISTRY, vol. 91, no. 6, 2004, pages 1249 - 59

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029358B2 (en) 2005-10-25 2015-05-12 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8633188B2 (en) 2005-10-25 2014-01-21 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8815851B2 (en) 2005-10-25 2014-08-26 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8546380B2 (en) 2005-10-25 2013-10-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8168630B2 (en) 2007-04-24 2012-05-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
US8895548B2 (en) 2007-04-24 2014-11-25 Shionogi & Co., Ltd. Pharmaceutical composition for treating alzheimer's disease
US8884062B2 (en) 2007-04-24 2014-11-11 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US9273053B2 (en) 2008-06-13 2016-03-01 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity
US9650371B2 (en) 2008-06-13 2017-05-16 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US9139594B2 (en) 2009-07-22 2015-09-22 Eisai R&D Management Co., Ltd. Fused aminodihydropyrimidone derivatives
US9079914B2 (en) 2009-07-22 2015-07-14 Eisai R&D Management Co., Ltd. Fused aminodihydro-oxazine derivatives
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
US9687494B2 (en) 2009-10-08 2017-06-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9029362B2 (en) 2009-10-08 2015-05-12 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9475785B2 (en) 2009-10-08 2016-10-25 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9290466B2 (en) 2009-12-11 2016-03-22 Shionogi & Co., Ltd. Oxazine derivatives
US9656974B2 (en) 2009-12-11 2017-05-23 Shionogi & Co., Ltd. Oxazine derivatives
JPWO2011071109A1 (en) * 2009-12-11 2013-04-22 塩野義製薬株式会社 Fused heterocyclic compounds having an amino group
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
JP2014501769A (en) * 2011-01-06 2014-01-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 Condensed aminodihydrothiazine derivatives
US8822455B2 (en) 2011-01-06 2014-09-02 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
WO2012093148A1 (en) * 2011-01-06 2012-07-12 Eisai R&D Management Co., Ltd Fused aminodihydrothiazine derivatives
WO2012100179A1 (en) * 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
CN103502231A (en) * 2011-01-21 2014-01-08 卫材R&D管理有限公司 Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
CN106632401B (en) * 2011-01-21 2020-12-29 卫材R&D管理有限公司 Methods and compounds for the synthesis of fused aminodihydrothiazine derivatives
KR101906466B1 (en) 2011-01-21 2018-10-10 에자이 알앤드디 매니지먼트 가부시키가이샤 Fused aminodihydrothiazine derivatives useful as bace inhibitors
US8802871B2 (en) 2011-01-21 2014-08-12 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
JP2014503001A (en) * 2011-01-21 2014-02-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods and compounds useful for the synthesis of fused aminodihydrothiazine derivatives
US8940734B2 (en) 2011-01-21 2015-01-27 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
RU2593756C2 (en) * 2011-01-21 2016-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Condensed aminodihydrothiazine derivatives applicable as bace inhibitors
US8962858B2 (en) 2011-01-21 2015-02-24 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
JP2016121177A (en) * 2011-01-21 2016-07-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods and compounds useful in synthesis of fused amino-dihydrothiazine derivatives
CN103328486B (en) * 2011-01-21 2016-08-17 卫材R&D管理有限公司 Can be used as the Aminodihydrothiazinederivative derivative condensed of BACE inhibitor
WO2012098461A1 (en) 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
US8592408B2 (en) 2011-01-21 2013-11-26 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
CN103328486A (en) * 2011-01-21 2013-09-25 卫材R&D管理有限公司 Fused aminodihydrothiazine derivatives useful as BACE inhibitors
WO2012098213A1 (en) 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives useful as bace inhibitors
US8426584B2 (en) 2011-01-21 2013-04-23 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US8338407B2 (en) 2011-01-21 2012-12-25 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
US9175013B2 (en) 2011-01-21 2015-11-03 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
JP2014520777A (en) * 2011-07-06 2014-08-25 エフ．ホフマン−ラ ロシュ アーゲー Cyclopropyl-fused-1,3-thiazepine as BACE1 and / or BACE2 inhibitor
CN103649083A (en) * 2011-07-06 2014-03-19 霍夫曼-拉罗奇有限公司 Cyclopropyl-fused-1,3-thiazepines as BACE 1 and/or BACE 2 inhibitors
US8927535B2 (en) 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
WO2013004676A1 (en) * 2011-07-06 2013-01-10 F. Hoffmann-La Roche Ag Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US9227942B2 (en) 2012-04-27 2016-01-05 Eisai R&D Management Co., Ltd. Method for producing 5-(difluoromethyl)pyrazine-2-carboxylic acid and production intermediate thereof
WO2014013076A1 (en) 2012-07-20 2014-01-23 Eisai R&D Management Co., Ltd. Hexahydropyrrolothiazine compounds
US9758513B2 (en) 2012-10-24 2017-09-12 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
JP2015535247A (en) * 2012-10-26 2015-12-10 イーライ リリー アンド カンパニー BACE inhibitor
US9475784B2 (en) 2012-12-19 2016-10-25 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production
WO2014098831A1 (en) 2012-12-19 2014-06-26 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
US9309263B2 (en) 2013-01-29 2016-04-12 Amgen Inc. Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof
US9296734B2 (en) 2013-03-01 2016-03-29 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
JP2016511258A (en) * 2013-03-01 2016-04-14 アムジエン・インコーポレーテツド Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9611261B2 (en) 2013-03-08 2017-04-04 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9096615B2 (en) 2013-07-30 2015-08-04 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2016149057A1 (en) * 2015-03-19 2016-09-22 Eli Lilly And Company Selective bace1 inhibitors
US9938266B2 (en) 2015-03-19 2018-04-10 Eli Lilly And Company Selective BACE1 inhibitors
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2018112083A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018112086A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
WO2018112084A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
WO2018112094A1 (en) 2016-12-15 2018-06-21 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
WO2018112081A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
US10889581B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
US10889579B2 (en) 2016-12-15 2021-01-12 Amgen Inc. Thiazine derivatives as β-secretase inhibitors and methods of use
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
US11021493B2 (en) 2016-12-15 2021-06-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use

Also Published As

Publication number Publication date
CO6480979A2 (en) 2012-07-16
JP2012532874A (en) 2012-12-20
AU2010270691B8 (en) 2013-11-28
PE20120632A1 (en) 2012-05-26
NZ596579A (en) 2013-12-20
ZA201109385B (en) 2013-05-29
TWI405765B (en) 2013-08-21
US20110009395A1 (en) 2011-01-13
US20120323001A1 (en) 2012-12-20
EP2451793A1 (en) 2012-05-16
MA33492B1 (en) 2012-08-01
TW201113289A (en) 2011-04-16
CA2764429C (en) 2014-11-18
KR20120027482A (en) 2012-03-21
KR101362557B1 (en) 2014-02-13
MX2012000510A (en) 2012-01-27
EA201270149A1 (en) 2012-06-29
CR20120011A (en) 2012-02-09
BR112012000525A2 (en) 2015-09-15
EP2451793B1 (en) 2016-11-02
CA2764429A1 (en) 2011-01-13
EA019892B1 (en) 2014-07-30
AU2010270691B2 (en) 2013-08-01
CN102471296A (en) 2012-05-23
CL2012000033A1 (en) 2012-09-14
DOP2012000004A (en) 2012-01-31
US8278441B2 (en) 2012-10-02
AR077277A1 (en) 2011-08-17
HN2012000012A (en) 2014-05-26
ECSP12011581A (en) 2012-02-29
TN2011000673A1 (en) 2013-05-24
IL216742A0 (en) 2012-03-01
SG177594A1 (en) 2012-02-28
JP5666578B2 (en) 2015-02-12
AU2010270691A1 (en) 2011-12-22
CN102471296B (en) 2014-11-12

Similar Documents

Publication Publication Date Title
AU2010270691B2 (en) BACE inhibitors
CA2723207C (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
TW201400491A (en) Tetrahydropyrrolothiazine compounds
KR101979534B1 (en) Tetrahydrofuran-fused aminohydrothiazine derivatives useful for the treatment of Alzheimer ' s disease
US9828390B2 (en) Tetrahydropyrrolo[3,4-D][1,3]thiazine-derivative as BACE inhibitor
US10080758B2 (en) Tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080030698.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10731890

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 596579

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2010270691

Country of ref document: AU

Ref document number: 2524/MUMNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2764429

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010270691

Country of ref document: AU

Date of ref document: 20100706

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11181064

Country of ref document: CO

REEP Request for entry into the european phase

Ref document number: 2010731890

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12012500023

Country of ref document: PH

Ref document number: 2010731890

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127000457

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012000033

Country of ref document: CL

Ref document number: 2012519660

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201000055

Country of ref document: TH

Ref document number: 000028-2012

Country of ref document: PE

Ref document number: MX/A/2012/000510

Country of ref document: MX

Ref document number: CR2012-000011

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 201270149

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012000525

Country of ref document: BR

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112012000525

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120109